Harvard Medical School Curriculum Vitae

Date Prepared: Oct 23rd, 2016

Name: Joaquim Bellmunt Molins

Office Address: Dana Farber Cancer Institute
450 Brookline Avenue, D1230, Boston, MA, 02215

Work Email: joaquim_bellmunt@dfci.harvard.edu

Work FAX: 617-632-2165

Medical Education

1982	M.D.	Medicine	Universitat Autònoma de Barcelona (Autonomous University of Barcelona), Spain
1989	PhD, *cum laude*	Immunology	Autonomous University of Barcelona

Postdoctoral Training

1984-1988	Internship and Residency	Medical Oncology	University Hospital Vall d'Hebron, Barcelona, Spain
09/87-10/87	Observer on Clinical Immunology Service	Medical Oncology	Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY

Faculty Academic Appointments

01/06-07/07	Assistant Professor	Medicine	Pompeu Fabra University , Barcelona, Spain
07/07-03/13	Associate Professor	Medicine	Pompeau Fabra University
10/07-10/08	Associate Professor	Urology	Autonomous University of Barcelona
05/09-09/09	Visiting Professor	Medicine	Harvard Medical School (HMS), Boston, MA
07/11-03/13	Visiting Associate Professor	Medicine	HMS
04/13-04/14	Lecturer on Medicine	Medicine	HMS
05/14-	Associate Professor	Medicine	HMS

Appointments at Hospitals/Affiliated Institutions

Past

01/89-12/95	Clinical Instructor in Medical Oncology	GU and Sarcoma Unit Medical Oncology Section	Vall d'Hebron University Hospital
01/96-01/06	Consultant in Medical Oncology	GU and Sarcoma Unit Medical Oncology Section	Vall d'Hebron University Hospital
01/06-03/13	Senior Staff Physician	Solid Tumor Oncology, Genitourinary/Gastrointestinal (GU/GI) Division of Oncology	Hospital del Mar, Barcelona, Spain

Current

06/13-present	Senior Staff Physician	Medical Oncology	DFCI
06/13-present	Associate Physician	Medicine	Brigham and Women's Hospital (BWH) Boston, MA

Other Professional Positions

1983-1984	Military Physician	Spanish Military Service
1995-2006	Senior Consultant for Oncology	Clínica Quirón, Barcelona (private practice)
1995-2013	Senior Consultant for Oncology (private healthcare insurance: *Assistència Sanitaria Colegial*)	Hospital SCIAS, Barcelona
1999	Advisory Board Member	Rhône-Poulenc Rorer International Prostate
2002-2005	Advisory Board Member (Amlita in bladder cancer)	Eli-Lilly
2002-2005	Advisory Board Member (Temsirolimus in renal cell carcinoma)	Wyeth
2002-2005	Advisory Board Member (Rad 001-everolimus-in renal cell carcinoma)	Novartis
2002-present	Advisory Board Member (GW016 in bladder cancer, GW786034 in renal cell carcinoma)	Glaxo-Smith-Kline
2002-present	Advisory Board Member (SU 11248- sunitinib-in kidney cancer)	Pfizer
2002-present	Advisory Board Member (BAY96-9006-sorafenib-in kidney cancer)	Bayer
2002-present	Advisory Board Member (Revlimid in prostate cancer)	Celgene
2002-present	Advisory Board Member	AcMc G250 as adjuvant in kidney cancer)
2002-present	Advisory Board Member (Bortezomib in prostate cancer)	Celgene
2002-present	Advisory Board Member 2002-present (Docetaxel in prostate cancer) 2010-present (Cabazitaxel in prostate cancer)	Sanofi-Aventis

2002-present	Advisory Board Member (Vinflunine in bladder cancer)	Pierre-Fabre
2006	Advisory Board Member	Bristol-Myers Squibb Prostate Cancer Advisory Board
2007-2012	Advisory Board Member (Nexavar)	Bayer Health Care
2008-2011	Advisory Board Member 2008-2010 (Abiraterone acetate) 2010-2011 (Abiraterone in prostate cancer)	Cougar-Janssen Biotechnology
2009-present	Advisory Board Member	ImClone Systems Strategic Scientific Council
2009-2011	Advisory Board Member (Trabectedin in prostate carcinoma)	Pharmamar
2010-present	Advisory Board Member (Sipuleucel in prostate and bladder cancer)	Dendreon
2012-present	Advisory Board Member (MDV3100-enzalutamide-in prostate cancer)	Astellas/medivation
2013	Advisory Board Member (Nivolumab –BMS03036- in RCC)	Bristol-Myers
2014-present	Advisory Board Member	Vertex Pharmaceuticals
2014-present	Advisory Board Member (immunotherapy in bladder)	Genentech/Roche
2014-present	Advisory Board Member (immunotherapy for bladder)	Merck
2015-present	Advisory Board Member (immunotherapy for bladder)	Pfizer

Major Administrative Leadership Positions

Local

1989-2005	Head of the GU and Sarcoma Areas	Vall d'Hebron
2006-2013	Section Chief, Solid Tumor Oncology (Genitourinary/Gastrointestinal [GU/GI])	Division of Oncology, Hospital del Mar
2013-Present	Present Director, Bladder Cancer Center	Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC)
2014-present	Director, Clinical Research Information System (CRIS) Database	DF/BWCC
2014-present	Director, Genitourinary Oncology Seminar Series	HMS
2015-present	Chairman, Gelb Center Lank Center of Genitourinary Oncology	DF/BWCC

International

2006-2011	Chairman, Advanced Bladder Cancer Committee	European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group

Committee Service

Local

1990-2006	Consultant in charge of GU and Sarcoma Committee	Hospital Vall d'Hebron Member
2006-2013	GU Committee	University Hospital del Mar Sub-Chair
2011-2012	Pharmacy Committee	University Hospital del Mar Member

National

1990-present	Committee Member	Spanish Oncology Genitourinary Group(SOGUG)
	2004-2009	President
1990-2006	Member	Spanish National Cooperative Germ Cell Tumour Group (GG)
1992	Committee Member (vocal—i.e., part of the jury board), PhD degree	Universitat Autònoma de Barcelona
1992-1996	Committee Member	Solid Tumor Intensification (SOLTI) Group
1992-2006	Committee Member	Spanish Investigative Group for Sarcomas
1997	Committee member (Secretary—i.e., representing the university), PhD degree report "	Universitat Autònoma de Barcelona
2001	Committee Member (vocal), PhD degree report "	Universitat Autònoma de Barcelona
2006	Committee Member (vocal), PhD degree report "Lluis Cecchini Rosell, qualified *cum laude*.	Universitat Autònoma de Barcelona
2006	Committee Member (vocal), PhD degree report. Presented by Pere Domingo, qualified *cum laude*.	Universitat Central de Barcelona

International

1997-2011	Committee for Advanced Bladder Cancer	European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group
	1997-2011	Member
	2006-2011	President
2005-Present	Committee Member, "Bladder Cancer Consensus"	International Consultation on Urological Diseases (ICUD)
2015-present	Committee Member, "Novel Therapeutics for Non-Muscle Invasive Bladder Cencer"	National Cancer Institute's Clinical Trials Planning Meeting

Professional Societies

1985-present	Sociedad Española de Oncología Médica (SEOM)	Member
1988-present	European Society of Medical Oncology (ESMO) 2003-present 2010, 2012	Faculty Member Scientific Programs Committee member
1996-present	American Society of Clinical Oncology (ASCO) 2004-2005, 2009-2012	Scientific Programs Committee member: Genitourinary Cancer

Grant Review Activities

2004	Danish Cancer Society (Kraeftens Bekaempelse),	Danish Cancer Society External Reviewer
2006	PF-7 Project, European Union	European Union External Reviewer
2010	National Cancer Research Institute (NCRI), Bladder Cancer Clinical Studies Group Progress Review Panel	NCRI, London, UK External Reviewer
2010-2012	Fondo de Investigaciones Sanitarias (FISS) (Health Research Fund), Spanish Healthcare System	Spanish National Institute of Health External Reviewer
2013-2015	Fondo de Investigaciones Sanitarias (FISS)(Health Research Fund), Spanish Healthcare System	Spanish National Institute of Health External Reviewer
2014-2015	BCAN. 2014/15 Young Investigator Award Scientific Review Group	

Editorial Activities

Ad Hoc Reviewer

Annals of Oncology
BJU International
Cancer
Clinical Genitourinary Oncology
European Journal of Cancer
European Urology
European Urology "Focus"
Journal of Clinical Oncology

Lancet Oncology
Medicina Clínica
Clinical Cancer Research
Nature Review in Clinical Oncology

Other Editorial Roles

2011	Editorial Board Member for GU	Journal of Clinical Oncology
2011	Editorial Board Member	European Urology
2011	Editorial Board Member	Cancer Treatment Reviews
2012	Editorial Board Member for GU Frontiers	Genitourinary Oncology
2015	Editorial Board Member	Bladder Journal

Report of Funded and Unfunded Projects

Funding Information

Past

1987 Biological Response Modifiers in Oncology, (MSKCC)CIRIT (Consejo Interdepartamental de Investigacion e Innovacon Tecnologica) visiting scholar grant EE87/1 from the Health Investigation Fund, Spanish Department of Health
Personal grant as a Visiting ScholarThe major goal of this grant was to serve as an observer at Oncology Department of MSKCC and assay on the subject of Biological Response Modifiers in Oncology (IL2).

1989 Monoclonal antibodies for the treatment of soft tissue sarcomas at MSKCC, New York CIRIT visiting scholar grant EE89/2 from the Health Investigation Fund, Spanish Department of Health
Personal grant as a Visiting ScholarThe major goal of this grant was to serve as an observer at Oncology Department of MSKCC and assay on the subject of Monoclonal antibodies for the treatment of soft tissue sarcomas (McAb against GD2).

1991 Prognostic factors in breast cancer with negative lymph nodes: role of DNA cytometry (ploidy and Sphase) of the expression of epidermal growth factor and hormonal receptorsGrant 91/8483 (3 years).
PI, FISS (Fondo Investigaciones Sanitarias)
The major goal of this grant is to study the impact of EGFR and hormonal receptors in survivalof lymphnode negative breast cancer. Results were published in Anticancer Research.

1993 The role of P-glicoprotein in the prognosis and treatment of bladder cancer. Grant 93/0539 (1 year)
PI, FISSThe major goal of this grant is to study the prognostic impact of P-glicoprotein in Bladder Cancer by means of immunohitochemistry of FFPE tissue of bladder cancer patients undergoing chemotherapy. This was published by Ribas,A and served as part of the PhD thesis of Dr.Pilar Vicente.

1995 Comparative clinical assay of Droloxifene versus Tamoxifene as first line hormonal treatment in advanced breast cancer. DRL301 (PI: A. L. Sole Calvo)
Clinical Trial AC(HG)35/1995
Co-investigator
The major goal of this study is to compare the performance of two estrogenic agents in first line therapy of Breast Ca. My role was the follow-up of patients, the data aquisition and analysis.

1995 Phase II study of high dose Ifosfamide as first line treatment for soft tissue sarcomas. SPBAV-IF/GM
PI, Clinical Trial AC(HG)22/1995
The major goal of this pharma-industry sponsored study is to evaluate in a Phase II fashion the effect of Ofosfamide in sarcomas as a first line treatment. I contributed to the design of the study as well as to patient accrual and result interpretation.

1996 Double blind aleatorized trial comparing arimidex and nolvadex with the combination of arimidex and nolvadex as adjuvant treatment in postmenopausal women with breast cancer. 1033IL/0029 (P.I: A.L. Sole Calvo)
Clinical Trial AC(HG)63/1996
Co-investigator
The major goal of this pharma-industry sponsored study is to compare two adjuvant treatments in breast cancer in postmenopausal women. I contributed to the design of the study as well as to patient accrual and result interpretation.

1996 Phase I-II clinical assay of Cisplatino-Taxol® and Gemcitabine in irresectable locally advanced or metastatic transitional carcinoma of the bladder (PI: J. Baselga)Clinical Trial AC(HG)67/1996
Co-investigator
The major goal of this study is to to approach the role of triple therapy in metastatic bladder cancer that posteriorly lead to the EORTC phase III 30987. Together with the other PI we developed the conception and design of the combination therapy.

1996 In vitro Chemosensitivity of different Taxol combinations in breast and bladder cancer.Hospital Vall d'Hebron Project PR(HG)61, 1996P.I.,
The major goal of this study is to examine the in vitro testing of response profile to different Taxol combinations in breast and bladder cancer cell lines. My role was to lead the project, supervise the lab experiments and provide interpretation of the findings.

1996 Prognostic value of c-erb-2, de P53, MDM2 and Rb-gene overexpression in response prediction to adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil 5FU(CMF) or fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC) in breast cancer patients.Hospital Vall d'Hebron Project PR(HG)30/1996
PI
The major goal of this project is to study of molecular factors (c-erb-2, de P53, MDM2 and Rb) by immunohistochemitry of FFPE and its correlation with outcome in breast cancer patients treated with adjuvant chemotherapy.My role was to lead the project, accrue patientsand interpret the findings.

1996 Amifostina and M-VAC in metastatic or unresectable urothelial bladder cancer. Pilot study H95.022
Clinical Trial AC(HG)42/1996
PI
The major goal of this study sponsored by pharma-industry is to evaluate the association of amifostina to conventional MVAC in advanced urothelial cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

1997 Phase II study of the combination vinorelbine-estramustine in hormone refractory prostate cancer patients, stage D3, not previously treated with chemotherapy.
Clinical Trial AC(HG)64/19979PM25995IN21
PI
The major goal of this pharma-industry sponsored study is to evaluate in a Phase II fashion the effect of combining vinorelbine-estramustine in hormone refractory prostate cancer patients as a first line treatment. I contributed to the design of the study as well as to patient accrual and result interpretation.

1997 Phase II study of high dose ifosfamide plus doxorrubicine as first line treatment in advanced adult soft tissue sarcomas. GEIS-2
Clinical Trial AC(HG)91/1997
PI
The major goal of this pharma-industry sponsored study is toevaluate in a Phase II fashion the effect of adding ifosfamide in high doses to doxorrubicine in patients with non-treated sarcomas (first line). I contributed to the design of the study as well as to patient accrual and result interpretation.

1998 Randomized phase III study of 3BEP versus 3BEP-1 EP, and the 5- versus 3-day scheme in good prognosis germ cell tumors.EORTC 30941 Clinical Trial AC(HG)21/1998
PI
The major goal of this trial is to to show non inferiority of three versus five day schedule in good prognosis germ cell tumors. As the local PI at my institution of that time (hospital Vall d'Hebron), I was in charge of accruing patients, assesing the response to treatment and trial monitorization.

1998 Randomized Phase III study of oral JM-216 + prednisone or prednisone alone in hormone refractory prostate cancer.
EORTC 30972 Clinical Trial AC(HG)58/1998
PI
The major goal of this study is to show superiority of an oral platinum analog (JM-216) plus prednisone over prednisone alone in hormone refractory prostate cancer. As the local PI at my institution of that time (hospital Vall d'Hebron), I was in charge of accruing patients, assesing the response to treatment and trial monitorization.

1999 Multicentric, open, prospective, non-controlled phase II, study of sequential treatment with high dose doxorubicine followed by high dose ifosfamide, as first line treatment in advanced adult soft tissue sarcomas.
Geiss-04 Clinical Trial AC(HG)81/1999
PI
The major goal of this multicenter, pharma-industry sponsored study is to evaluate sequential treatment with doxorubicine and high dose ifosfamide in previously nontreated patients. I contributed to the design of the study as well as to patient accrual and result interpretation.

1999 Phase II study of semaxinib (SU5416) in locally advanced or metastatic soft tissue sarcomas.
ND 029903 S/S Clinical Trial AC(HG)75/1999
PI
The major goal of this pharma-industry sponsored study is to evaluate the role of a potent and selective VEGFR inhibitor in sarcomas after failure of first line schedule. I contributed to the design of the study as well as to patient accrual and result interpretation.

1999 Phase II study of SU5416 in locally advanced or metastatic renal clear cell carcinoma.
SOGUC99/01 Clinical Trial AC(HG)74/1999
PI
The major goal of this study is address the role of an antiangiogenic drug (SU5416) in locally advanced or metastatic RCC. As the local PI at my institution of that time (hospital Vall d'Hebron), I was in charge of accruing patients, assesing the response to treatment and trial monitorization.

2000 Phase II study of ET-743 as second or third line treatment for advanced or metastatic adult soft tissue sarcomas. ET-B-010-99 Clinical Trial AC(HG)37/2000
PI
The major goal of this study is to test the efficacy of ectenasceidina (currently called trabectedin) in sarcomas. As the local PI at my institution of that time (hospital Vall d'Hebron), I was in charge of accruing patients, assesing the response to treatment and trial monitorization.

2002-2005 Role of the androgen and estrogen transporter protein and of the estrogen receptors in the development and progression of prostate cancer. PI: Francina Munell.FISS Grant 020772FISS (2002-2005)
Co-Investigator
The major goal of this study is to analayze the levels of ERbeta1 and ERbeta2 throughout the cell cycle, as well as the mechanisms of action and the consequences of the over-expression of ERbeta1 in the human prostate cancer LNCaP cell line. My role was to co-lead the project with Dr.Reventos, supervise the Lab experiments and provide interpretation of the findings.

2005 TV3-Marathon Grant (2005) Prostate cancer. PI: Anna Messeguer.
(The Marathon Grant is a yearly grant sponsored by the main TV channel in Catalunya.)
Co-investigator
The major goal of this grant is to assess the role of human hepatitis A virus cellular receptor 1 (hHAVcr-1) as a differentially expressed gene in ccRCC and its potential use as a target for therapy of these tumors. My role was to co-lead the project with Dr.Reventos, supervise the lab experiments and provide interpretation of the findings.

2006-2007 Phase I/II study of the 15 day combination of Alimta and cisplatin in patients with irresectable and locally advanced or metastatic urothelial cancer.
Lilly, S.A (H3E-ES-S085)
PI
The major goal of this pharma-industry sponsored study is to evaluate in a Phase I/II manner the chemotherapy combination of pemetrexed with cisplatin in advanced (irresectableor metastatic) urothelial carcinoma. I participated in the design of the study as well as accruing patients and interpreting the results.

2006-2008 Phase II study of Yondelis in men with advanced prostate cancer.
Pharma Mar, S.A (ET-B-025-02)
PI
The major goal of this study is to evaluate the recently FDA approved chemotherapy agent trabectedin (Yondelis), in advanced prostate cancer. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

2006-2009 Correlation of clinical/metabolical response with imaging methods and perfusion analysis based on methionine and oxygen 15-water positron emission tomography/computed tomography (PET/CT).Grant PI061239 (). SU11248 (sunitinib) pharmacodynamics in bladder transitional cell carcinoma
PI
The major goal of this study is to use PET/CT imaging of patients to track metabolic changes and correlate them with imaging in patients with advanced bladder cancer. I designed the study and was in chargeof patient accrual and data analysis.

2007-2009 Phase II open, multicenter study of CNTO 328 (Monoclonal Antibody Anti-IL6) in combination with mitoxantrona versus mitoxantrona alone in patients with metastatic hormone-resistant prostate cancer (CPHR).
Janssen-Cilag S.A (C0328T07)
PI
The major goal of this pharma-industry sponsored study is to evaluate th addition of a moniclonal anti-IL6 to mitoxantrona alone in patients with metastatic hormone-resistant prostate cancer (CPHR). I participated in the design of the study as well as accruing patients and interpreting the results.

2007-2010 Phase III Multicenter, randomized, double blind study of bevacizumab in combination with capecitabina and cisplatin compared to placebo in combination with capecitabina and cisplatin, as first line treatment in patients with advanced gastric carcinoma.
Roche Farma, S.A. (BO20904/AVF4200g)
PI
The major goal of this pharma-industry sponsored study is to evaluate in a Phase III the role of adding an antiangiogenic agent (bevacizumab) to chemotherapy in gastric carcinoma. I contributed to patient accrual and result interpretation.

2007-2011 Pilot Phase II open study, non-controlled and multicenter, to evaluate efficacy and safety of the combination of cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil) as neoadjuvant treatment followed by concomitant chemoradiotherapy (cisplatin) combined with cetuximab in patients with locoregional esophageal cancer.Grupo TTD (TTD-06-02)
PI
The major goal of this study is to test efficacy and safety of combination therapy in esophageal cancer. I contributed to the design and data interpretation.

2007-2012 Multicenter, randomized, double blind study, to compare the efficacy and safety of aflibercept against placebo administered every 3 weeks in patients with metastatic hormone-resistant prostate cancer treated with docetaxel/prednisone.
Sanofi-Aventis, S.A (EFC6546)
PI
The major goal of this pharma-industry sponsored study is to evaluate the role of adding aflibercept to chemotherapy with docetaxel in CRPC. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2009 Phase I clinical study of dose escalation of the combination of gemcitabin, capecitabin and sunitinib in the treatment of patients with unresectable or metastatic kidney carcinoma.
Spanish Group For The Study Of Genitourinary Cancer (SOGUG 07-02)
PI
The major goal of this study is to test antiangogenics combined with chemotherapy in non surgical or metastatic kidney cancer. I contributed to the design, patient acrual and data/results interpretation.

2008-2009 Multicenter, open, expanded access program of RAD001, in patients with metastatic renal carcinoma progressing after therapy with tirosine kinase inhibitor of epidermal growth factor receptor (EGFR).
Novartis Farmacéutica, S.A (CRAD001L2401)
PI
The major goal of this pharma-industry sponsored study is to evaluate in a Phase II fashion the effect of adding ifosfamide in high doses to doxorrubicine in patients with non-treated sarcomas (first line). I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2010 Phase II study (only one arm) of pralatrexate in patients with advanced or metastatic transitional cell carcinoma of the bladder.
Allos Therapeutics, Inc. (PDX 011)
PI
The major goal of this Phase II pharma-industry sponsored study is to evaluate pralatrexate in patients with advanced or metastatic bladder cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2010 Prospective study of prognostic factors of response to sunitinib in patients with renal clear cell carcinoma.*Grupo Español Para El Estudio Del Cancer Genitourinario* (SUT-REN-07)
PI
The major goal of this study is to identify factors predictive of response to antiangiogenic agents in RCC. I designed the study and contributed to patient accrual and interpretation of the data.

2008-2010 Phase I study of Sunitib Malate in combination with cisplatin and 5-Fluoruracil in patients with advanced gastric carcinoma.
Pfizer, S.A (A6181128)
PI
The major goal of this pharma-industry sponsored study is to evaluate the combination of an antiangiogenic (Sunitinib) with cisplatin and 5-Fluoruracil in gastric cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2010 Multicenter, non-comparative, Phase II (in 2 steps) study to evaluate efficacy, safety and pharmacokinetics of AZD4877 administered weekly in patients with recurrent and advanced urothelial carcinoma.
Astrazeneca (D2782C00010)
PI
The major goal of this Phase II study sponsored by pharma-industry is to evaluate AZD4877in advanced urothelial cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2012 Multinational, randomized, double blind study to compare the efficacy of aflibercept every 2 weeks against placebo in patients with metastatic colorectal carcinoma (CCRM) treated with the combination of irinotecan/5-FU (FOLFIRI), after oxaliplatin failure.
Sanofi-Aventis, S.A (EFC10262)
PI
The major goal of this study sponsored by pharma-industry is to evaluate aflibercept added to standard FOLFIRI in metastatic colorectal cancer in second line. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2012 Randomized study of larotaxel + cisplatin (lc) versus gemcitabine + cisplatin (gc) in the first line treatment of locally advanced or metastatic urothelial or bladder cancer.
Sanofi-Aventis, S.A (EFC6668).
PI
The major goal of this pharma-industry sponsored study is to evaluate larotaxel + cisplatin (lc) versus gemcitabine + cisplatin (gc) as initial treatment of advanced/metastaticurothelial cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2008-2012 Randomized phase II study of the combination of LY2181308-sodium and docetaxel against docetaxel hormone-resistant prostate cancer.
Lilly, S.A (H8Z-MC-JACR)
PI
The major goal of this Phase II study sponsored by pharma-industry is to evaluate the addition of LY2181308-sodium to docetaxel in hormone-resistant prostate cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2009-2012 RAPTOR: Phase II randomized multicenter study of RAD001 in a single group with monotherapy for the treatment of advanced renal cell papilar carcinoma.
Novartis Farmacéutica, S.A (CRAD001LFR08)
PI
The major goal of this pharma-industry sponsored study is to evaluate monotherapy with RAD001 in advanced renal cell papilar carcinoma. I contributed to the design of the study as well as to patient accrual and result interpretation.

2009-2014 Phase III randomized double blind, placebo controlled of abiraterone acetate (CB7630) plus prednisone in patients asymtomatic or with minor symptoms with advanced metastatic castration resistant prostate cancer.
Cougar Biotechnology, Inc (COU-AA-302)
PI
The major goal of this Phase III pharma-industry sponsored study is to evaluate abiraterone in castration resistant prostate cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2010-2012 Phase III study to evaluate efficacy and safety of docetaxel and prednisone with or without lenalidomid in patients with castration resistant prostate cancer (CPRC).
Celgene International Sarl (CC-5013-PC-002).
PI
The major goal of this Phase III pharma-industry sponsored study is to evaluate the addition of lenalidomid to docetaxel/prednisone in hormone-resistant prostate cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2010-2012 Phase II, randomized study of IMC-3G3, a monoclonal anti-platelet-derived growth factor receptor (PDGFR) alpha human antibody, plus mitoxantrone and prednisone against mitoxantrone and prednisone in castration resistant prostate cancer in the event of progression or intolerance to docetaxel based chemotherapy.
Imclone Systems Inc. (IMCL CP15-0805).
PI
The major goal of this Phase II study sponsored by pharma-industry is to evaluate the addition of an anti-PDGFR to mitoxantrone/prednisone after docetaxel in castration resistant prostate cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2010-2012 Clinic and Pharmacokinetic Phase II study of PM00104 (Zalypsis®) in patients with advanced and/or metastatic urothelial carcinoma in progression after Platinum based first line treatment.
Pharma Mar, S.A (PM104-B-004-10
PI
The major goal of this Phase II study sponsored by pharma-industry is to evaluate the role of PM00104 as second line treatment in urothelial cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2010-2013 Phase II open, multicenter, non-randomized study to explore TKI258 in patients with advanced urothelial carcinoma with mutated fibroblast growth factor receptor 3 (FGFR3) or wild-type FGFR3.
Novartis Farmacéutica, S.A (CTKI258A2201).
PI
The major goal of this Phase II study sponsored by pharma-industry evaluating TKI258 in patients with advanced urothelial carcinoma with mutated fibroblast growth factor receptor 3 (FGFR3) or wild-type FGFR3. I contributed to the design of the study as well as to patient accrual and result interpretation.

2011-2012 Open study of abiraterone acetate in patients with castration resistant prostate cancer with progression after chemotherapy with taxanes.
JANSSEN-CILAG S.A (212082PCR3001)
PI
The major goal of this pharma-industry sponsored study is to evaluate abiraterone after taxanes in hormone-resistant prostate cancer. I contributed to the design of the study as well as to patient accrual and result interpretation.

2011-2012 Research Intensification Program from the SNS 2012. *Fondo De Investigación Sanitaria*.
ISCIII (INT11/302)
PI
The major goal of this grant is to support 50% of salary and allows to hire a PhD.

2006-2013 RETIC (Cooperative net for research in cancer). Spanish col.laborative research on GU projects at H.del Mar, *Fondo De Investigación Sanitaria*. Acquired resistance to the anti-EGFR monoclonal antibody centuximab in colorectal cancer. Co-PI: Albanell Mestres, Joan ISCIII (RD06/0020/0109).
Co-PI, $437,054
The major goal of this study is to examine mechanisms of resistance of colorectal cancer to anti EGFR substances. Together with Dr.Albanell we co-directed the project, designed the protocol and interpreted the results.

2009-2013 Research group in Oncologic Experimental Therapy. Co-PI: Albanell Mestres, Joan.Catalan col.laborative research on GU projects at H. del Mar, *Agència De Gestió Ajuts Universitaris De Recerca* (2009 SGR 321).
Co-PI, $62, 060
The major goal of this grant is to expand on all areas of oncology by financing 50% of the salary of a PhD. This grant is supported by public institutions in Spain.

2010-2013 Molecular predictive factors to chemotherapy response in urothelial tumors: miRNAs as molecular factors predicting platinum responseFISS Grant
PI $81, 661 (ongoing)
The major goal of this grant is to study the role of the small molecules (miRNAs) in bladder cancer patients treated with platinum based chemotherapy and gorup as extreme responders (good and poor outcome). I designed the protocol and supervised the research and am in charge of interpretation of the reuslts.

2011-2013 Phase II randomized trial comparing vinflunine as monotherapy against maintenance therapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium that have benefited from first line treatment with the combination of cisplatin plus gemcitabine.
Grupo Español Para El Estudio Del Cancer Genitourinario (SOGUG2011/02)
PI $3,243
The major goal of this study was a multicenter effort to study second line treatment with vinflunine in advanced urothelial cancer. I designedthe study and was in charge of the supervision of the centers accruing patients as well as accruing my own cases and interpreting data.

2011-2013 Phase III, open, multicenter, randomized study to compare efficacy and safety of TKI258 against sorafenib, in patients with metastatic renal cell carcinoma after failure of antiangiogenic tharapies (mTOR inhibitor and targeted VEGF therapies).
Novartis Farmacéutica, S.A (CTKI258A2302)
PI
The major goal of this study is to compare antitirosinkinases (TKI258) with antiangiogenics (Sorafenib) after other antiangiogenics in MRCC. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

2011-2013 Patients With Progressive Metastatic Prostate Cancer (PREVAIL): Multinational, phase III, randomized, double blind, placebo controlled trial on the efficacy and safety of oral MDV3100 in patients without previous chemotherapy and with metastatic prostate cancer non responders to androgen deprivation.
Medivation Inc (MDV3100-03).
PI $105,738 (ongoing)
The major goal of this study is to evaluate MDV3100 in patients without previous chemotherapy and with metastatic prostate cancer non responders to androgen deprivation. I contributed to the design of the protocol, am involved in accrual of cases and will interpret the results.

2011-2013 Phase II, randomized trial to evaluate the combination of vinflunin plus gemcitabine and vinflunin plus carboplatin in patients non eligible for cisplatin with advanced or metastatic transitional urothelial carcinoma.
Pierre Fabre Iberica (L00070 IN 213 P1)
PI $ 21, 749
The major goal of this study is to compare two combinations of vinflunine (gemcitabine vs carboplatin) in patients with advanced urothelial cancer unfit for cisplatin. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

2011-2014 Phase III, randomized, double blind, multicenter trial comparing Orteronel (TAK-700) plus prednisone against placebo plus prednisone in patients with metastatic hormone resistant prostate cancer not previously treated with chemotherapy.
Millennium Pharmaceuticals, INC (C21004)
PI $92,078 (ongoing; closed to patient accrual, on follow up)
The major goal of this phase III study sponsored by Pharma industry is to evaluate the addition of Orteronel in metastatic CRPC (prostate cancer). I contributed to the design of the protocol, accrual of cases and will partcipate in interpretation of the findings.

2011-2014 Phase II open, randomized trial of GDC-0980 against everolimus in patients with metastatic renal cell carcinoma that have progressed during or after VEGF targeted therapy.
Genentech, Inc. (PIM4973g).
PI $73, 943 (my role has ended)
The major goal of this study is to evaluate GDC-0980 against everolimus in patients with metastatic RCC progressing to VEGF. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

2012-2014 Phase II, randomized, double blind to compare gemcitabine and cisplatin in combination with OGX-427 or placebo in patients with advanced transitional cell carcinoma.
Oncogenex Technologies Inc (OGX-427-02).
PI $82, 378 (ongoing; role as European P.I.)
The major goal of this study is to evaluate the addition of OGX-427 to Gem-cis in advanced urothelial cancer. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

2013-2014 Evaluating the functional consequences –recurrence and progression- of epigenetic mutations derived from pT1G3 (HGT1) bladder tumor sequencingFriends of Dana-Farber Cancer Institute
PI
The major goal of this study is to identify those patients with high-risk non-muscle invasive bladder cancer (HGT1 tumors) who are curable with early intervention at the time of first diagnosis. This is a joint effort with the Broad Institute. I contributed to the design of the study as well as the cases and FFPE tumor blocs and we are currently interpreting the findings.

Current

2011-2016 Phase II, randomized, double blind, placebo controlled trial to evaluate safety and efficacy of ASCI recMAGE-A3 + AS15 in patients with muscle invasive bladder cancer MAGE-A3 positive after cistectomy.
Chiltern International Spain S.A (EAURF2010-01).
PI $31, 912 (ongoing)
The major goal of this study is to evaluate safety and efficacy of ASCI recMAGE-A3 + AS15 in patients with muscle invasive bladder cancer MAGE A3 positive after cistectomy. I contributed to the design of the protocol and accrual of cases and will do so with interpretation of results at the end.

2011-2016 Randomized, open, multicenter trial comparing cabazitaxel 25 mg/m2 and 20 mg/m2, administered in combination with prednisone every 3 weeks, with docetaxel in combination with prednisone in patients with metastatic hormone resistant prostate cancer not previously treated with chemotherapy. Sanofi-Aventis, S.A (EFC11784)
PI $121, 000
The major goal of this study is to evaluate the addition of different doses of cabazitaxel CRPC. I contributed to the design of the protocol, accrual of cases and will also participate in interpretation of findings.

2012-2016 Efficacy, phase II, randomized, double blind trial of PROSTVAC-V/F ± FEC GM in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer.Bn Immunotherapeutics Inc (BNIT-PRV-301)
PI $26, 488 (my role has ended)
The major goal of this study is to evaluate PROSTVAC-V/F ± FEC GM in men with asymptomatic or minimally symptomatic metastatic CRPC. I contributed to the design of the protocol, accrual of cases and interpretation of findings.

Current Unfunded Projects

2011-2018 PI/SCOT-Short duration oncological treatmentTrial on adjuvant chemotherapy in colorectal cancer. Caiber- Plataforma Española De Ensayos Clínicos (SCOT)

2012- PI/ Antitumor and molecular effects of MLN0128 (TORC1/2 Inhibitor) and MLN1117 (PI3K Inhibitor) inhibitors of the PI3K/mTOR signaling pathway in human bladder cancer: role of PI3K mutations. University Hospital del Mar-Institut Hospital del Mar d'Investigacions Mèdiques (IMIM).
Preclinical laboratory of the molecular therapeutics and biomarkers in cancer. *Fundació Institut Mar d'Investigacions Mèdiques*. (ongoing)

2013- PI/PROFILE
The major effort at DFCI to scan tumor tissue from cancer patients for hundreds of gene mutations linked to cancer): using OncoMap and other clinical/research data for analysis in non-prostate GU tumors (Urothelial transitional/non-transitional, penile, adrenal, and kidney) in collaboration with Dr Toni K Choueiri.

2013- Chairman/GELB Center
CRIS Database: Design of the new Bladder cancer research information system (CRIS) project at Dana-Farber, to store clinical, treatment, and outcomes data for cancer patients treated through Dana-Farber/Partners Cancer Care

Report of Local Teaching and Training

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2007-3/2013	Monday Seminar Hospital Staff and Residents	University Hospital del Mar 1 hour contact time, every nine weeks
2007-3/2013	Tuesday Seminar Research fellows, pre-docs and post-docs	University Hospital del Mar 1 hour contact time, weekly
4/2013-	Mentorship Fellows and Medical Students	Dana-Farber Cancer Institute 1-2 hours/week

Clinical Supervisory and Training Responsibilities

1989-12/2005	Attending in charge of GU and Sarcoma area at Hospital Vall d'Hebron	40 hours/week
2006-3/2013	Primary supervisory MD for one oncology resident, University Hospital del Mar	Monday and Wednesday clinic (all day, 18 patients)
2007-3/2013	Primary supervisory MD for one Assistant Physician, Department of Medical Oncology, University Hospital del Mar	Meetings every 15 days
4/2013-current	Clinical supervisory role at DFCI/BWH, training junior faculty, fellows and residents, etc.	Approximately 2 hrs/day of clinical training out of 40+ hour work week

Laboratory and Other Research Supervisory and Training Responsibilities

1996	Supervision of fellow preparing PhD degree report "*Valor de la determinación de la P-Glicoproteina en el cáncer de vejiga*" (Usefulness of P-G licoprotein determination in Bladder Cancer,) presented at Universitat Autònoma de Barcelona and qualified cum laude. My role was to supervise the fellow throughout all the process, including study design, data analysis, and the final version of the manuscript.	Approximately 2-3 hours per week
2006-3/2013	Supervision of college students, clinical research coordinators and medical students, in teaching about clinical protocols, conducting research, experimental design, and trials interpretation. University Hospital del Mar	Varied levels of mentorship, from daily to weekly, lasting from a few months to several years
2006-3/2013	Supervision of oncology fellows in preparing grant applications, preparing manuscripts, preparing PowerPoint presentations in GU cancers	Varied levels of mentorship from weekly to daily, lasting from a few weeks to 1 year
2012-5/2013	Supervision of fellow preparing PhD Degree report "Anti tumor effects of novel targeted therapies against PI3K-AKT-mTOR pathway and definition of molecular markers associated with drug sensibility in human bladder cancer models." Presented at Universitat Pompeu Fabra. My role was to supervise the fellow throughout all the process, including study design, data analysis, and the final version of the manuscript	Approximately 2-3 hours per week
4/2013-2015	Mentoring a Masters's in Public Health student on the project "Adjuvant Chemotherapy for Invasive Bladder cancer: an updated systematic review and meta-analysis of 8 randomized trials" at Dana-Farber Cancer Institute. My role has been to supervise the fellow throughout all the process, including study design, and the final version of the manuscript. Two publications have been published in Journal of Clinical Oncology and European Urology.	Approximately 2-3 hours per week
2015-	Mentoring the predoc Anna Hernandez for her doctoral Thesis: "Predicting response to the TSC1/TSC2 TAK 128 in human bladder cancer cell lines"	Aproximately 2-3 hours per week

Formally Supervised Trainees

2000-2005	Joan Albanell, MD, PhD/ Professor of Medicine, Autonomous University of Barcelona (Spain) Project mentor regarding the role of prognostic factors in breast cancer (1 paper)
2006-3/2013	Clara Montagut, MD/ Attending and Research Associate at University Hospital del Mar, Barcelona (Spain) Project mentor regarding Cetuximab resistance in CRC (1 paper in Nature Medicine)
2009-2012	Marta Guix, MD/ Instructor in Medicine, University Hospital del Mar, Barcelona (Spain) Project mentor regarding the role of prognostic factors in bladder cancer (1 Poster presentation at ASCO)
2011-2012	Francesc Pons, MD/ Instructor in Medicine, University Hospital del Mar, Barcelona (Spain) Project mentor regarding the role of postpazopanib therapy in renal cell carcinoma (RCC) (ESMO Poster). Development of Retrospective International Study of Invasive/ Advanced Cancer of the Urothelium (RISC) database in bladder cancer.

Formal Teaching of Peers (e.g., CME and other continuing education courses)

Those presentations below sponsored by outside entities are so noted and the sponsor is identified in parentheses.

2008	Update on targeted therapies in renal cell carcinoma (RCC). Genitourinary EORTC Meeting	Barcelona
2008-2010	Targeted therapies in renal cell carcinoma (RCC). Annual Master Class in Urologic Oncology, European School of Urology- European Association of Urology (ESU-EAU)	Barcelona
2008-2010	New treatment for advanced bladder cancer Advancements in Genitourinary Cancers Courses coincidental with EAU Annual meeting	Milan, Italy (2008), Stockholm, Sweden (2009), Barcelona, Spain(2010)
2010	Targeted therapies in RCC ESU Masterclass in Medical Oncology	Lugano, Switzerland
2012	Update on GU oncology Euroarb School of Oncology (ESO)	Amman, Jordan
2015	Immunotherapy in Bladder Cancer. Non-ASCO activity. CME accredited	Chicago
2015	PDL1/PD1 Trials in Bladder Cancer, SBUR 2015 Fall Symposium.	Fort Lauderdale, FL

Report of International Invited Teaching and Presentations

Those presentations below sponsored by outside entities are so noted and the sponsor is identified in parentheses.

1999	Gemzar+Taxol+Cisplatin Advanced Bladder Cancer/ Lecture Lilly Oncology Young Investigators' MeetingIndianapolis, IN
1999	New Chemotherapeutic Agents in Prostate Cancer/ Lecture 1ST Combined Symposium In Breast And Prostate Cancer, Barcelona, Spain
2000	Gemzar+Taxol+Cisplatin in Advanced Bladder Cancer/ Lecture 2000 Oncology Global Meeting Conference, Indianapolis, IN
2001	Adjuvant Treatment in Bladder Cancer/ Lecture Convegno Nazionale, Il Trattamento Del Carcinoma Vescicale, Rome, Italy
2002	Magistral Lecture,State Of The Art In The Management Of Urological Malignancies/ Lecture and Session ChairBarcelona, Spain
2002	Promising New Agents and Strategies for Bladder Cancer Perspectives In Bladder Cancer/ LectureLisbon, Portugal
2002	Role of Adjuvant and Neo-Adjuvant Strategies in Muscle Invasive Bladder Cancer, Perspectives In Bladder Cancer/ LectureLisbon, Portugal
2003	State of the Art in the Treatment of Bladder Cancer, European School Of Oncology (ESO) Course/ LectureRome, Italy
2003	State of the Art Lectures on Urological Malignancies/ Chemotherapy of Advanced Bladder Cancer/ LectureGhent, Belgium
2003	Genitourinary Cancer-Non-Prostate/Discussant, Poster Session39th Annual Meeting. ASCO, Chicago, IL
2004	Angiogenesis Inhibitors : Background/ Lecture XIXth Congress of the European Association of Urology (EAU) European Society for Urological Research (ESUR), Vienna, Austria
2004	Rationale of phase III/ Vinflunine Investigators Meeting/ LectureParis, France
2004	Genitourinary Cancer-Non-Prostate/ Discussant, Poster Session40th Anual Meeting ASCO, New Orleans, LA
2004	Targeting Angiogenesis Symposium/ III European Spring Oncology Conference (ESOC 2004)/ Lecture and Session ChairMarbella, Málaga (Spain)
2004	Hormone-refractory Prostate Cancer / LectureVIII Symposium Of The Portuguese Association of Urology ,Funchal, Madeira Island
2004	Rationale and Results of Epidermal Growth Factor Receptor (EGFR) Antagonists in Urothelial Cancer/LectureInternational Symposium "Targeted Cancer Therapies: One Year of Progress" Nice, France
2004	Molecular Correlates for Advanced Bladder Cancer/ Lecture 4TH Annual Perspectives In Bladder Cancer, Seville, Spain

2004	Oncology Highlights": A multicenter Phase III comparison of docetaxel + prednisone (P) and mitoxantrone (MTZ) + P in patients with androgen-independent prostate cancer (AIPC): Secondary analysis of survival in patient subgroups The TAX 327 Investigators (ASCO 2004, Abstr. 4), Ronald de Wit, NL / Discussant 29TH ESMO Congress, Vienna, Austria
2005	Adjuvant Chemotherapy in Bladder Cancer / Lecture IV Workshop of Urologic Oncology, Espinho, Portugal
2005	Changing Paradigms and Challenges in the Management of Urothelial Cancer/ /Faculty Member and Education Session Speaker 41th Annual Meeting, ASCO, Orlando, FL
2005	Genitourinary (Nonprostate) Cancer/ Oral Presentation, Session Co-Chair 41th Anual Meeting. ASCO, Orlando, FL
2005	Changing Paradigms and Challenges in the Management of Urothelial Cancer/ Lecture 41th Anual Meeting, ASCO,Education Session, Orlando, FL
2005	A Paradigm Shift in the Management of Androgen-Independent Prostate Cancer (AIPC)/Lecture 1ST Sanofi Aventis Asian Oncology Forum, Shanghai, China
2005	Paclitaxel, Cisplatin and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium/LectureTen Years Of Gemcitabine In The Treatment Of Solid Tumors ,Monastier Hospital, Italy
2005	Age Should Not Be an Obstacle for Appropriate Treatment of Prostate Cancer/ Lecture 6TH Meeting Of The International Society of Geriatric Oncology, Geneva, Switzerland
2005	Chemotherapy of Metastatic Disease-Can We Improve Survival? / Lecture 57 Kongress Der Deutschen Gesellschaft Fur Urologie E. V., Düsseldorf, Germany
2005	Education Session, Advanced Bladder Cancer/ Lecture 42nd Annual Meeting ASCO, Orlando, FL
2008	Efficacy and Safety of First-line Bevacizumab (BEV) Plus Interferon-a2a (IFN) in Patients (pts) >65 years with Metastatic Renal Cell Carcinoma (mRCC)/ PresenterASCO Annual Meeting GU Kidney Cancer ,San Francisco, CA
2008	Randomized Phase III trial of Vinflunine (V) Plus Best Supportive care (B)vs B Alone as 2nd Line Therapy After a Platinum-containing Regimen in Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)/ PresenterASCO Annual Meeting,New Orleans, LA
2010	Optimizing Systemic Therapy for Advanced Urothelial Cancer/ Lecture ASCO Genitourinary Cancers Symposium, San Francisco, CA
2011	Computational Biology in Bladder Cancer/LecturePost-ASCO Symposium ,Barcelona, Spain
2011	Models to Predict Prognosis in Advanced Disease/ Chair ESO-MSKCC, 2nd Interdisciplinary Conference Prostate Cancer: Predictive Models for Decision Making, MSKCC, New York
2011	6th European International Kidney Cancer Symposium/ Lecture Kidney Cancer Association , Warsaw, Poland
2011	Localized Invasive Bladder Cancer: Neo-adjuvant Chemotherapy/ Lecture Educational Cancer Convention Lugano (ECCLU), Lugano, Switzerland

2011	Treatment Options for a Patient with Locally Advanced But Unresectable Bladder Cancer and for a Patient with Muscle-invasive but with Mixed Histology or Predominantly Nontransitional Cell/ LectureASCO Annual Meeting, Chicago, IL
2011	Developing the Next Generation of Bladder Cancer Trials: Paths to Success/ Panel Discussant Bladder Cancer Think Tank (Bladder Cancer Advocacy Network (BCAN) Meeting, San Diego, CA
2011	Genitourinary Malignancies-Prostate Cancer: Androgen Receptor/Chair & Speaker European Cancer Congress (ECCO)-ESMO 2011,Stockholm, Sweden
2011	The Role of mTOR Inhibitor in RCC Treatment: Sequencing & Future perspectives/ LectureThai Society of Clinical Oncology (TSCO) Annual Meeting, Pattaya, Thailand
2011	Embracing Excellence in Prostate, Bladder and Kidney Cancer/LectureUpdate on bladder cancer/ Plenary Session, 3rd European Multidisciplinary Meeting on Urological Cancers (EMUC), Barcelona, Spain
2011	Landscape and Current Optimal Treatment for Advanced Renal Cell Cancer (RCC)/ Lecture Renal Cell Cancer Experts Meeting of Oncologists, Seoul, Korea
2011	Consensus Conference on Prostate Cancer; ESMO Prostate Cancer Guidelines/ Lecture European Society of Medical Oncology (ESMO), Zurich, Switzerland
2012	Recent Updates in Prostate Cancer: How to Choose the Treatment in the Metastatic Setting/ Lecture Euro-Asian Society of Oncology (EASO), Red Sea Seminar in Clinical Oncology Ain Sokhna, Egypt
2012	Options for the Treatment-Naive Patient / Moderator 11th International Kidney Cancer Symposium Kidney Cancer AssociationChicago, IL
2013	How to Choose Among the Various New Agents? Sequencing treatments in mCRPC/ LectureGlobal Expert Forum Advances in Prostate Cancer, Vienna, Austria
2013	Advances in the Management of Metastatic Urothelial Cancer / Lecture V InterAmerican Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies, Buenos Aires, Argentina
2013	Current and Future Treatments in Metastatic Renal Cancer/ Lecture V InterAmerican Oncology Conference: Current Status and Future of Anti-Cancer Targeted Therapies, Buenos Aires, Argentina
2014	Best of ASCO GU. Bladder Cancer/ Lecture Madrid Spain
2015	Prostate Cancer Today and Tomorrow: The Medical Oncologist's contribution/ Lecture Bergamo Hospitals, Bergamo Italy
2015	The role of Novel Agents in mCRPC Treatment; Selecting the Optimal First Line Treatment in mCRPC/ Lecture Janssen Satellite Symposium, Brazilian Cancer Society Meeting, Brasilia, Brazil
2015	Immunotherapy in Bladder Cancer: Results and Ongoing Clinical Trials/ Lecture Oncology Satellite Symposium, ECCO, Vienna Austria

2015	State of the Art in Urothelial Cancers/ Lecture Boehringer Ingelheim's Conversation in Oncology, Riviera Maya, Mexico
2015	Non-Muscle Invasive Bladder Cancer lecture. Bethesda. NCI
2015	Summit in Urolotelial Cancer. Pierre Fabre Oncosymposium. Geneva
2015	Lecture on Immunotherapy in Bladder Cancer. Brazilian National Congress. Brasilia. Brazil
2015	Combination Immunotherapy in GU Oncology. Hospital Clinic of Barcelona.
2015	Advances in Bladder Cancer. National SEOM Congress. Madrid.
2015	GU malignancies. A year in Review. ESMO Asia. Singapore.
2016	Post ASCO-GU. Sponsorized by Pierre Fabre. Turin
2016	Join Meeting EAU-Japanese Urological/Oncology Society. EAU Meeting. Munich.
2016	Immonotherapy in Bladder Cancer. Lebanon. MSD.

Report of Clinical Activities and Innovations

Current Licensure and Certification

1982	Medical Licensure, Barcelona, Spain
1989	Spanish Certificate for Medical Oncology Specialty
2010	Accredited Professor of Medicine NAQAA (National Agency for Quality Assessment and Accreditation) (ANECA)
2012	ECFMG Certificate (Educational Commission for Foreign Medical Graduates) Certificate number 0-797-330-8: Step 1, March 2012; Step 2 CK, May 2012; and Step 2 CS, July 2012
2013	Temporary Faculty License as a Associate Professor in Medicine approved by the Board of Registration in Medicine of the Commonwealth of Massachusetts since May 2013

Practice Activities

Past

1989-2005	Ambulatory Care	Medical Oncology Hospital Vall d'Hebron	2.5 full day outpatient clinics, with 6-8 new patients and 50-55 follow-up patients per week
1989-2005	Inpatient Care	Genitourinary Cancers Hospital Vall d'Hebron	2 month inpatient attending a year. Two months of inpatient consultation for genitourinary cancers at the General Vall d'Hebrón Hospital.
2005-2013	Ambulatory Care Section Chief of Medical Oncology	Hospital del Mar	Two full-day clinics, with 4 new patients and 25-30 follow-up patients per week.
2005-2013	Inpatient Care Section Chief of	Hospital del Mar	Inpatient consultation for genitourinary cancers at Hospital del Mar.

	Medical Oncology		
Present			
2013-	Ambulatory Care	Genitourinary Oncology, Dana-Farber Cancer Institute	Eight half-day clinic sessions, with 8 new patients per week.
2013	Inpatient care	Brigham and Women's Hospital, Boston, MA	4 weeks per year.

Clinical Innovations

Clinical Innovations and Quality Improvement:

Starting in October 1987, when returning from MSKCC as a clinical observer, I started the Genitourinary Tumors Unit at the Vall d'Hebron Hospital. At that time, there was no established treatment for bladder tumors, and patients received only supportive care. The multidisciplinary team approach was established at that time. My interest during my oncological career has focused on the development of systemic treatment for bladder cancer and the search for prognostic factors and potential therapeutic targets. On a more practical clinical level, I have participated in initiatives to computerize medical records, including chemotherapy entry. I regularly met with my clinical trials team (project manager, research nurses, and research coordinators) to discuss clinical care/updates regarding patients enrolled in trials on a weekly basis (30-60 min.). I also mentored 2 Junior Staff members in the GU section. As a Section Chief at Hospital del Mar, I organized weekly meetings (60 min) with all the GU and GI Team to discuss ongoing clinical trials, clinical protocol reviews, and means to better provide high quality cancer care to patients.Based on my work in genitourinary tumors and my clinical expertise, I am part of the EORTC, ESMO and EAU Committees that develop Clinical Guidelines. I am a panel member, leading or co-authoring ESMO Bladder Guidelines (Lead), EORTC RCC Guidelines (Co-author), EAU Prostate Cancer Guidelines (Co-author) and ICUD (Interntional Consensus on Urological Diseases) Guidelines (Co-author), and SIOG (International Society of Geriatric Oncology) Task Force. All these Guidelines are considered a European and worldwide authoritative source and the arbiter of high-quality cancer care. I have also led Guidelines on RCC in the National SOGUG Group.

Clinical Innovations (2013-)

Currently at DFCI, I am Director of the Bladder Cancer Center within the Lank Cancer Center for Genitourinary Oncology. My responsibilities began in April 2013 and are in development. My aims are to improve the diagnostic tools in bladder cancer, as well as increase enrollment of patients in clinical trials and develop a more multidisciplinary approach with the Radiotherapy and Urology Departments. The prospective CRIS clinical/biological (online) database has been built, and its implementation was finalized in autumn 2013. This increases the coverage of the overall CRIS project, which already exists for prostate and kidney patients. In addition, a retrospective data collection of cystectomies has been approved by the ethics committee to build the subsequent prospective collection of fresh frozen bladder specimens (DFCI Protocol No.: 13-293). This innovative work has been the focus of interest from other institutions.

In Clinical trials: an IST has been approved and is now going through IRB based on the preclinical data generated in the lab with the compound MLN128. The goal is to study the synergistic activity of paclitaxel and MLN128 in patients failing firstline chemotherapy for bladder cancer.

A second IST is now being reviewed by our IRB. This a phase I trial combining B-701 (a monoclonal antibody against FGFR3) with the anti PD1 agent pembrolizumab.

The grant proposal on HGT1 NMIBC (non-muscle invasive bladder cancer) to develop a predictive genomic signature (join effort with scientists at the DFCI Center for Cancer Genome Discovery (CCGD) (Dr McConnail and Hummelen) and the DFCI/BWH Center for Molecular Oncologic Pathology (CMOP) (Dr Bowden) and with Broad investigator (DR Kwiatkowski. My involvement on translational research is evolving, having set up genomic projects in the area of urothelial tumors with CMOP, CCGD and individuals at the Broad Institute. The prognostic/predictive value of the OncoMap platform is being analyzed, integrating the DFCI (Dr. Ross´s) cohort, the 2009 Spanish cohort (OncoMap 2-3) and also the PROFILE cohort. For this last one, a Gelp proposal has been approved for patients with urothelial cancer. A paper summarizing the findings was published in PLosOne. Finally, the metanalysis on "Adjuvant Chemotherapy for Invasive Bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials" that we have worked on with Dr. Leow, a Master's in Public Health student, was published by the *European Urology* journal. Another meta-analysis of prognostic factors in HGT1 tumors was published in Journal Of Clinical Oncology in 2015.

Report of Scholarship

Peer reviewed publications in print or other media

1. Navarro M, **Bellmunt J**, Balana C, Colomer R, Jolis L, del Campo JM. Mitomycin-C and vinblastine in advanced breast cancer. Oncology. 1989; 46(3):137-42.

2. **Bellmunt J**, Knobel H, Navarro M, Jolis L. Nailfold capillary microscopy and bleomycin-induced vascular toxicity. Cancer Invest. 1990;8(6):641.

3. **Bellmunt J**, Morales S, Navarro M, Sole LA. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol. 1990;26 Suppl:S81-4.

4. **Bellmunt J**, Navarro M, Morales S, Jolis L, Carulla J, Knobell H, Vilardell M, Sole LA. Capillary microscopy is a potentially useful method for detecting bleomycin vascular toxicity. Cancer. 1990; 65(2):303-9.

5. Felip E, **Bellmunt J**, Salud A, Capdevila F. Symptomatic hypomagnesemia in a patient treated with cisplatin. Med Clin (Barc). 1990; 95(5):196-7.

6. **Bellmunt J**, De Gracia J, Morales S, Orriols R, Tallada N. Cytologic diagnosis in bronchoalveolar lavage specimens. A diagnostic technique for lung neoplasmas with a peripheral location. Chest. 1990; 98(2):513-4.

7. **Bellmunt J**, Albanell J, Gallego OS, Vicente P. Antineoplastic chemotherapy in digestive tumors Med Clin (Barc). 1991; 97(9):358.

8. **Bellmunt J**, Sole L. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991;14 Suppl 2:S36-9.

9. **Bellmunt J**, Morales S, Albanell J, Gallego O. Nail-fold capillary microscopy and chemotherapy-induced vascular toxicity. Ann Oncol. 1991; 2(4):310.

10. Navarro M, Mur E, Jolis L, **Bellmunt J**, Bodi R, Sole LA, Rubio D. Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung. Rev Clin Esp. 1991; 189(5):209-12.

11. Rovirosa A, Salud A, Felip E, Capdevila F, Giralt J, **Bellmunt J**. Cavitary pulmonary metastases in transitional cell carcinoma of the urinary bladder. Urol Int. 1992; 48(1):102-4.

12. **Bellmunt J**, Albanell J, Salud A, Espanol T, Morales S, Sole-Calvo LA. Interferon and disseminated Langerhans cell histiocytosis.Med Pediatr Oncol. 1992; 20(4):336-7.

13. Albanell J, Gallego OS, **Bellmunt J**, Vicente P, Morales S, Sole LA. Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide.Rev Clin Esp. 1992; 190(9):463-5.

14. Vicente P, Rovirosa A, Gallego O, Albanell J, **Bellmunt J**, Sole LA. Spinal cord compression as a primary manifestation of occult thyroid carcinoma. An Med Interna. 1992; 9(7):334-6.

15. 87Rovirosa Casino A, **Bellmunt J**, Salud A, Vicente P, Maldonado J, Bodi R, Salvador L. Endobronchial metastases in colorectal adenocarcinoma. Tumori. 1992; 78(4):270-3.

16. **Bellmunt J**, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, De Torres J, Morote J, Lopez M, Sole LA. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy .Cancer. 1992; 70(7):1974-9.

17. de Gracia J, Bravo C, Miravitlles M, Tallada N, Orriols R, **Bellmunt J**, Vendrell M, Morell F. Diagnostic value of bronchoalveolar lavage in peripheral lung cancer. Am Rev Respir Dis. 1993; 147(3):649-52.

18. Vicente P, **Bellmunt J**, Ruiz-Marcellan C, Garcia A, Rovirosa A, Sole LA. Primary non-Hodgkin's lymphoma of the breast. Med Clin (Barc). 1993; 101(7):261-3.

19. Vicente P, **Bellmunt J**, de Torres I. Glycoprotein P and resistance to antitumor chemotherapy. Med Clin (Barc). 1993; 101(20):785-8.

20. Gallego-Melcon S, Sanchez de Toledo J, Doste D, Lopez D, Moraga F, Rodriguez C, Vidal T, **Bellmunt J**. Late recurrent metastasis in Wilms' tumour. Med Pediatr Oncol. 1994;23(2):158-61.

21. Rovirosa A, **Bellmunt J**, Lopez A, Fernandez M, Guerra M, Montagut J. The incidence of second

neoplasms in advanced laryngeal cancer. Impact on survival Med Clin (Barc). 1994; 102(4):121-4.

22. Vila A, **Bellmunt J**, Rilo A, Saballs P. Bilateral choroidal metastasis as a form of presentation of pulmonary carcinoma Med Clin **(**Barc). 1994; 102(5):196-7.

23. **Bellmunt J**, Ribas A, Ocana I, Capdevila JA, Ruiz-Marcellan MC, Giralt J, Sole LA. Initial clinicopathological manifestations of malignant lymphoproliferative processes in patients with human immunodeficiency virus seropositivity. Study of 40 cases] An Med Interna. 1994; 11(5):217-23.

24. Ribas A, **Bellmunt J**. Gene therapy: new prospects in the treatment of cancer Med Clin (Barc). 1994; 103(20):776-9.

25. Ribas A, **Bellmunt J**, Sole LA, Ribas-Mundo M. Corticoid treatment in Castleman's disease Med Clin (Barc). 1995; 105(16):638-9.

26. Ribas A, **Bellmunt J**, Albanell J, Capdevila JA, Ocana I, Gallego OS, Maldonado J, Giralt J, Sole LA. Malignant lymphoproliferative diseases in HIV-seropositive patients. A study of 40 cases at a single institution in Spain. Acta Oncol. 1995; 34(1):75-82.

27. Sole LA, Albanell J, **Bellmunt J**, Ribas A, Gallego OS, Carulla J. Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer. 1995; 75(3):831-5.

28. Eres N, **Bellmunt J**. The clinical importance of the fibroblast growth factor (bFGF) as a biological marker and therapeutic modulator. Future applications. Med Clin (Barc). 1996; 107(8):296-8.

29. Albanell J, **Bellmunt J**, Molina R, Garcia M, Caragol I, Bermejo B, Ribas A, Carulla J, Gallego OS, Espanol T, Sole Calvo LA. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996; 16(2):1027-32.

30. Ribas A, Albanell J, **Bellmunt J**, Sole-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol. 1996; 14(5):1573-80.

31. **Bellmunt J**, Ribas A, Albanell J, Bermejo B, Vera R, De Torres JA, Morote J, Lopez-Pacios MA, Banus JM, Rovirosa A, Carulla J, Sole LA. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am J Clin Oncol. 1996; 19(4):344-8.

32. Salud A, Porcel JM, Rovirosa A, **Bellmunt J**. Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol. 1996; 62(4):249-52.

33. Ribas A, **Bellmunt J**, Albanell J, De Torres I, Bermejo B, De Torres JA, Morote J, Gallardo E, Vera R, Carulla J, Sole-Calvo LA. Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI). Tumori. 1996; 82(6):554-9.

34. **Bellmunt J**, Eres N, Ribas A, Casado S, Albanell J, Baselga J. Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol. 1997;40(3):273-6.

35. Ribas A, Gallardo E, Vera R, Casado S, Vidal R, **Bellmunt J**. Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clin Oncol (R Coll Radiol). 1997;9(4):269-70.

36. Ribas A, Albanell J, **Bellmunt J**, Bermejo B, Gallardo E, Vera R, Bodi R, Sole-Calvo LA. Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule. Acta Oncol. 1997; 36(7):701-4.

37. **Bellmunt J**, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, Baselga J. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997; 80(10):1966-72.

38. Eres N, **Bellmunt J**. Regulatory proteins of the cell cycle: alterations in the cycline D1 pathway as a paradigm. Findings in breast cancer. Med Clin (Barc). 1998; 111(15):592-6.

39. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, **Bellmunt J**, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16(2):453-61.

40. Ribas A, Albanell J, Sole-Calvo LA, Gallardo E, **Bellmunt J**, Vera R, Vidal R, Carulla J, Baselga J. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma. Cancer. 1998; 82(5):878-85.

41. Molina R, Segui MA, Climent MA, **Bellmunt J**, Albanelll J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Peiro G, Perez-Picanol E, Ballesta AM. p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res. 1998; 18(1B):507-11.

42. Buesa JM, Lopez-Pousa A, Martin J, Anton A, Garcia del Muro J, **Bellmunt J**, Arranz F, Valenti V, Escudero P, Menendez D, Casado A, Poveda A. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 1998; 9(8):871-6.

43. **Bellmunt J**, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortes-Funes H, Baselga J. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer. 2000; 36 Suppl 2:17-25.

44. Cos J, **Bellmunt J**, Soler C, Ribas A, Lluis JM, Murio JE, Margarit C. Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line. Cancer Invest. 2000;18(5):429-35.

45. **Bellmunt J**, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Batiste-Alentorn E, Saenz A, Lopez-Brea M, Font A, Nogue M, Bastus R, Climent MA, de la Cruz JJ, Albanell J, Banus JM, Gallardo E, Diaz-Rubio E, Cortes-Funes H, Baselga J. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000; 18(18):3247-55.

46. **Bellmunt J**, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol. 2001; 11(5):517-22.

47. **Bellmunt J**, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer. 2001; 37(17):2212-5.

48. Morote J, **Bellmunt J**. Bone alkaline phosphatase serum level predicts the response to antiandrogen withdrawal. Eur Urol. 2002; 41(3):257-61.

49. **Bellmunt J**, Cos J, Cleries R, Perez M, Ribas A, Eres N, Murio JE, Margarit C, Baselga J. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest. 2002; 20(5-6):673-85.

50. **Bellmunt J**, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortes-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002; 95(4):751-7.

51. **Bellmunt J**, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003; 46 Suppl:S85-104.

52. **Bellmunt J**, de Wit R, Albiol S, Tabernero J, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003; 47(2):195-206.

53. Albiol S, **Bellmunt J**. Advanced bladder cancer: new therapeutic strategies. Med Clin (Barc). 2003; 120(2):68-77.

54. de Wit R, **Bellmunt J**. Overview of gemcitabine triplets in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003; 45(2):191-7.

55. Vila MR, Kaplan GG, Feigelstock D, Nadal M, Morote J, Porta R, **Bellmunt J**, Meseguer A. Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int. 2004; 65(5):1761-73.

56. Tabernero J, Rojo F, Marimon I, Voi M, Albanell J, Guix M, Vazquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, **Bellmunt J**, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, Garcia M, Valverde S, Baselga J. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2005; 23(11):2521-33.

57. Sternberg CN, Krainer M, Oh WK, Bracarda S, **Bellmunt J**, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007; 99(1):22-7.

58. **Bellmunt J**, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J, Taron M, Rosell R, Baselga J. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007; 18(3):522-8.

59. de Bono JS, **Bellmunt J**, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients

with hormone-refractory prostate cancer. J Clin Oncol. 2007; 25(3):257-62.

60. Anderson J, Van Poppel H, **Bellmunt J**, Miller K, Droz JP, Fitzpatrick JM. Chemotherapy for older patients with prostate cancer**.** BJU Int. 2007 Feb;99(2):269-73.

61. **Bellmunt J**, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategi**es** in the **tr**eatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007 Feb;99(2):274-80.

62. Orsola A, Cecchini L, **Bellmunt J**. Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007 Mar 22;356(12):1276. (letter to the Editor)

63. **Bellmunt J,** Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol**.** 2007 Apr;34(2):135-44.

64. Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, **Bellmunt J;** Spanish Oncology Genito Urinary Group Study Group. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007 Aug;18(8):1359-62.

65. **Bellmunt J,** Albiol S, Albanell J. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. BJU Int. 2007 Sep;100(3):490-2.

66. **Bellmunt J**, González-Larriba JL, Climent MA, López-Vivanco G, Urruticoechea L, Albanell J. Sorafenib TARGET trial results in Spanish patients. Clin Transl Oncol**.** 2007 Oct;9(10):671-3.

67. Hurtado A, Pinós T, Barbosa-Desongles A, López-Avilés S, Barquinero J, Petriz J, Santamaria-Martínez A, Morote J, de Torres I, **Bellmunt J**, Reventós J, Munell F. Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol**.** 2008;30(4):349-65.

68. **Bellmunt J**, Albiol S, Kataja V; ESMO Guidelines Working Group. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol**.** 2008 May;19 Suppl 2:ii47-8.

69. **Bellmunt J**, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol. 2008 Aug;19(8):1387-92.

70. **Bellmunt J**, Hautmann RE. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol. 2008 Nov;54(5):1192-7.

71. **Bellmunt J**. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol. 2008 Nov;54(5):1192-7. (Editorial)

72. Cebrian V, Alvarez M, Aleman A, Palou J, **Bellmunt J**, Gonzalez-Peramato P, Cordón-Cardo C, García J, Piulats JM, Sánchez-Carbayo M. Discovery of myopodin methylation in bladder cancer. J Pathol. 2008 Sep;216(1):111-9.

73. Aleman A, Cebrian V, Alvarez M, Lopez V, Orenses E, Lopez-Serra L, Algaba F, **Bellmunt J**, López-Beltrán A, González-Peramato P, Cordón-Cardo C, García J, del Muro JG, esteller M,

Sánchez-Carbayo M. Identification of PMF 1 methylation in association with bladder cancer progression. Clin Cancer Res. 2008 Dec 15;14(24):8236-43.

74. **Bellmunt J**, Négrier S, Escudier B, Awada A, Aapro M.The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72.

75. **Bellmunt J**, Carles J, Albanell J. Predictive modelling in hormone-refracory prostate cancer (HRPC). Clin Transl Oncol. 2009 Feb;11(2):82-5

76. **Bellmunt J**, Albiol S, Suárez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol. 2009 Mar;69(3):211-22.

77. **Bellmunt J**, Albiol S, Kataka V, ESMO Guidelines Working Group. Invasive bladder cancer: ESMO clinical recommendations for diangosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:79-80.

78. **Bellmunt J**. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009 Jun;55(6):1310-2. (Editorial)

79. **Bellmunt J**, Ribas A. Editorial comment on: Vaccine Therapy in patients with renal cell carcinoma. Eur Urol. 2009 Jun;55(6):1342-3 . (Editorial)

80. **Bellmunt J**, Flodgren P, Roigas J, Oudard S. Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int, 2009 Jul;104(1):10-8.

81. Stenberg CN, Dumez H, Van Poppel H, Shoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D, Van Oosterom AT, de Reijke TM, De Santis M, Verbaeys A, Ringeisen F, **Bellmunt J**, Albers P, Calais-da-Silva F; EORTC Genitourinary Tract Cancer Group. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer**.** Ann Oncol. 2009 Jul;20(7):1264-9.

82. Choueiri TK, **Bellmunt J**. Sunitinib in renal-cell carcinmoma: explanded indications. Lancet Oncol. 2009 Aug;10(8):740. (Editorial)

83. **Bellmunt J**, Rosenber JE, Choueiri TK. Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol. 2009 Oct;56(4):606-8. (Editorial)

84. **Bellmunt J**, Macià F, Malmusi D, Llorente JA, Carles J, Lloreta J, Foro P, Gelabert A, Albanell J, Castells X. Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients. Eur J Cancer. 2009 Nov;45(16):2804-9.

85. De Santis M, **Bellmunt J**, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/carboplatin and methrotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit"for cisplatin-based chemotherapy: phase II—results of EORTC study 30986. J Clin Oncol. 2009 Nov 20; 27(33):5634-9

86. **Bellmunt J**, Théodore C, Demkow T, Kopmyakov B, Dengelov L, Daugaard G, Caty A, Carles j,

Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H. Phase III trial of vinfluvine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20;27(27):4454-61. Erratum in J Clin Oncol. 2010 Jan 1;28(1):182.

87. Colomer R, Alba E, González-Martín A, Paz-Ares L, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, **Bellmunt J**, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J, Spanish Society of Medical Oncology. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010 Feb;21(2):195-8.

88. Porta C, **Bellmunt J**, Eisen T, Szczylik C, Mulders P. Tretating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010 Feb;36(1):16-23.

89. Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martínez-Fernández A, Martínez-Avilés L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, rovira A, Rojo F, **Bellmunt J**, Albanell J. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010 Mar 30;102(7):1137-44.

90. Sanjuán X, Salas A, Lloreta J, **Bellmunt J**, Manchon Walsh P. Colorectal Cancer OncoGuia Group. Colorectal Cancer OncoGuia: Surgical pathology report guidelines. Clin Trans Oncol. 2010 Mar;12(3):211-3.

91. **Bellmunt J**, Trigo JM, Calvo E, Carles J, Pérez-Grácia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J. Activity of a multitargeted chemo-switch regimen (sorafinib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr; 11(4):350-7.

92. **Bellmunt J**, Choueiri TK, Fougeray R, Schutz FA, Salí Y, Winquist E, Culine S, Von der Amase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens**.** J Clin Oncol. 2010 Apr 2010 28(11):1850-5.

93. Choueiri TK, Schutz FA, Je Y Rosenberg JE, **Bellmunt J**. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010 May 1;28(13):2280-5.

94. Escudier B, **Bellmunt J**, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010 May 1;28(13):2280-5.

95. Manchon Walsh P, Borràs JM, Ferro T, **Bellmunt J**, Espinàs JA. Colorectal Cancer Oncoguia**.** Clin Transi Oncol. 2010Mar; 12(3):188-210. Erratum in: Clin Tranl Oncol, 2010 Jun;12(6):456.

96. **Bellmunt J**, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther**.** 2010 Jun;10(6):825-

35.

97. **Bellmunt J**, Maroto-Rey P, trigo JM, Carles J, Guillem V, López-Martín JA, Antón-Torres A, Urruticoechea L. A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01 Clin Trans Oncol. 2010 Jul; 12(7):503-8.

98. Martin-Broto J, Gutiérrez A, García-del-Muro X, López-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andrés R, Casado A, Tejido PG, Blanco R, Carles J, **Bellmunt J**, Gómez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (FRS) in localized GIST: a Spanish Group of Sarcoma Research (GEIS) Study. Ann Oncol. 2010 Jul;21(7):1552-7.

99. Schmidinger M, **Bellmunt J**, Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Aug;36(5):416-24.

100. Calvo E, Maroto P, del Muro XG, Climent MA, González-Larriba jL, esteban E, López R, Paz-Ares L, **Bellmunt J**, Castellano D. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:11-20.

101. Calvo E. Maroto P, del Muro XG, Climent MA, Gonzalez-Larriba JL, Esteban E, López R, Paz-Ares L, **Bellmunt J**, Castellano D. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev. 2010 Aug;29 Suppl 1:1-10.

102. Négrier S, Jäger E, Porta C, McDermott D, Moore M, **Bellmunt J**, Anderson S, Cihon F, Lewis J, Escudier B, Bukowski R. Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET. Med Oncol. 2010 Sep; 27(3):899-906.

103. Hutson TE, **Bellmunt J**, Porta C, Szczylik C, Staehler M, Nadel A, Anderson S, Bukowsky R, Eisen T, Escudier B. TARGET Clinical Trial Group. Long-Term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur. J. Cancer. 2010 Sep;46(13):2432-40.

104. Ruppen I, Grau L, Orenes-Piñeiro E, Ashman K, Gil M, Algaba F, **Bellmunt J**, Sánchez-Carbayo M. differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ 138 cells transfected with metastasis suppressor KiSS-1 gene. Mol Cell Proteomics. 2010 Oct;9(10):2276-91.

105. **Bellmunt J**, Guix M. New agents for bladder cancer. Ann Oncol. 2010 Oct;21 Suppl 7:vii56-vii58.

106. Dutcher JP, Tannir N, **Bellmunt J**, Escudier B. Experience with sorafenib and the elderly patient. Med Oncol. 2010 Dec;27(4):1359-70.

107. Mickisch GH, Schwander B, Escudier B, **Bellmunt J**, Maroto JP, Porta C, Walzer S, Siebert U. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-

line metastatic renal cell carcinoma therapy. Clinicoecon Outcomes Res. 2011;3:19-27.

108.Bracarda S, **Bellmunt J**, Melichar B, Négrier S, Bajetta E, Ravaud A, Sneller V, Escudier B. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011 Jan; 107(2): 214-9.

109.Choueiri TK, Mayer EL, JE Y, Rosenberg JE, Nguyen PL, Azzi GR, **Bellmunt J**, Burstein HJ, Schutz FA. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Onc; 2011 Feb 20;29(6):632-8.

110.**Bellmunt J**, Choueiri TK, Schutz FA, Rosenberg JE. Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and ptifalls. Ann Oncol. 2011 Feb;22(2);245-**7**. (Editorial)

111.Galsky MD, Jahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Stenberg C, Bajorin DF, **Bellmunt J**. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3): 211-4.

112.**Bellmunt J**, González-Larriba JL, prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011 Mar 21.

113.**Bellmunt J**, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr;78(1):24-32.

114.Di Lorenzo G, Porta C, **Bellmunt J,** Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C.Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011 Apr;59(4):526-40.

115.Fitzpatrick JM, **Bellmunt J**, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr;107 Suppl 2:1-12.

116.**Bellmunt J**, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2011 Apr;107(8):1190-9.

117.Fitzpatrick JM, **Bellmunt J**, Dreicer R, Fleshner NE, Logoethics CJ Moul JW, Tombal B, Zlotta A. Maximizing outcomes in genitourinary cancers across the treatment continuum. BJU Int. 2011 Apr;107 Suppl 2:1-12.

118.Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, **Bellmunt J**.Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy**.** J Clin Oncol. 2011 Jun 10;29(17):2432-8.

119.Pons F, Orsola A, Morote J, **Bellmunt J**. Variant Forms of Bladder Cancer: Basic Considerations of Treatment Approaches. Curr Oncol Rep. 2011 Jun;13(3):216-21.

120.Karakiewicz PL, Sun M, **Bellmunt J**, Sneller V, Escudier B. Prediction of Progression-Free Survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: Comparison of a nomogram to the Motzer criteria. Eur Urol. 2011 Jul;60(1):48-56.

121.Schutz FA. **Bellmunt J**, Rosenberg JE, Choueiri TK. Vinfluvine: drug safety evaluation of this novel synthetic vinca alkaloid. Expert Opin Drug Saf. 2011 Jul;10(4):645-53.

122.**Bellmunt J**. What are the expected developments in the medical treatment of bladder cancer. Eur J Cancer. 2011 Sep;47 Suppl 3:S294-7. (Editorial)

123.Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, **Bellmunt J**, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011 Nov;12(12):1143-50.

124.De Santis M, **Bellmunt J**, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. J Clin Oncol. 2012 Jan 10;30(2):191-9.

125.Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Somasekar S, Serrano S, Himmelbauer H, **Bellmunt J**, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med. 2012 Jan 22;18(2):221-3.

126.Galsky MD, Chen GJ, Oh WK, **Bellmunt J,** Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb;23(2):406-10.

127.Joniau S, Abrahamsson PA, **Bellmunt J**, Figdor C, Hamdy F, Verhagen P, Vogelzang NJ, Wirth M, Van Poppel H, Osanto S. Current vaccination strategies for prostate cancer. Eur Urol. 2012 Feb;61(2):290-306.

128.Bahl A, **Bellmunt J**, Oudard S. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 2012 Mar;109 Suppl 2:14-9.

129.**Bellmunt J**, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W.Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 2012 Mar;109 Suppl 2:8-13.

130.Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, **Bellmunt J**, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012 Mar;23(3):664-70

131.Paz-Ares L, López-Pousa A, Poveda A, Balañá C, Ciruelos E, **Bellmunt J**, Del Muro JG,

Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tantovic A, Cortes-Funes H, Buesa JM. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone**.** Invest New Drugs. 2012 Apr;30(2):729-40.

132.**Bellmunt J**, Von der Maase H, Mead GH, Skoneczna I, de SantisM, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman L R, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, and de Wit R. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC Intergroup Study 30987. J Clin Oncol. 2012 Apr 1;30(10):1107-13.

133.Gore ME, **Bellmunt J**, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S. Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. Eur J Cancer. 2012 May;48(7):1038-47.

134.Michaelson MD, **Bellmunt J**, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2012 May;23(5):1234-40

135.Krajewski KM, Fougeray R, **Bellmunt J**, Pons F, Schutz FA, Rosenberg JE, Salhi Y, Choueiri TK. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul;48(10):1495-502

136.Morales-Barrera R, **Bellmunt J**, Suárez C, Valverde C, Guix M, Serrano C, Gallén M, Carles J. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012 Aug;48(12):1816-21.

137.Soukup V, Babjuk M, **Bellmunt J**, Dalbagni G, Giannarini G, Hakenberg OW, Herr H, Lechevallier E, Ribal MJ. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature**.** Eur Urol. 2012 Aug;62(2):290-302.

138.Sonpavde G, **Bellmunt J**, Schutz F, Choueiri TK. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep. 2012 Aug;14(4):295-306.

139.Castellano D, Carles J, Esteban E, Trigo JM, Climent MÁ, Maroto JP, del Muro XG, Font A, Paz-Ares L, Arranz JÁ, **Bellmunt J**. Recommendations for the optimal management of early and advanced urothelial carcinoma. Cancer Treat Rev. 2012 Aug;38(5):431-41.

140.Sternberg CN, **Bellmunt J**, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings**.** Eur Urol. 2012 Aug 14.

141.Meeks JJ, **Bellmunt J**, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol**.** 2012 Sep;62(3):523-33.

142. Castellano D, **Bellmunt J**. The optimize project: beyond first-line therapy in metastatic renal cell carcinoma. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S1-2.

143. González Larriba JL, Espinosa E, García Carbonero I, García-Donas J, López M, Meana A, Puente J, **Bellmunt J**. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S11-7.

144. Wagner M, **Bellmunt J**, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K. False Positive 2-(18)Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Disseminated Seminoma and Post-Chemotherapy Residual Masses. Clin Genitourin Cancer. 2012 Sep 12. pii: S1558-7673(12)00169-3.

145. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, Alasino C, Bella S, Carraro S, Geist M, Abdi E, Begbie S, Briscoe K, Davis I, Dowling A, Ganju V, Gurney H, Hovey E, Ng S, Nottage M, Rosenthal M, Stockler M, Tan T, Wong S, Young R, Krainer M, Loidl W, Machiels J, Mebis J, Renard V, Dumez H, Van Aelst F, Werbrouck P, Ellard S, Joshua A, Karakiewicz P, Lacombe L, Lattouf JB, Michels J, Mukherjee S, Ruether D, Venner P, Winquist E, Wood L, Aren O, Gonzalez P, Pastor P, Baumgaertner I, Beuzeboc P, Bompas E, Boyle H, Colombel M, Delva R, Eymard J, Gravis G, Guillot A, Houédé N, Joly F, Kaphan R, Loriot Y, Oudard S, Priou F, Tartas S, Theodore C, Tourani JM, Voog E, Bögemann M, Hadaschik B, Hammerer P, Heidenreich A, Holzer W, Merseburger A, Stenzl A, Steuber T, Suttmann H, Trojan L, Wirth M, Cerbone L, Conte P, Passalacqua R, Tucci M, Gerritsen W, Jassem J, Kalinka-Warzocha E, Olubiec J, De Bruyne R, Malan J, Vorobiof D, **Bellmunt J**, Carles J, Durán I, Font A, Gil-Bazo I, Maroto J, Bahl A, Choudhury A, Hoskin P, James N, Jones R, Mazhar D, O'Sullivan J, Payne H, Pedley I, Protheroe A, Waxman J, Zivi A, Alexander B, Appleman L, Aragon-Ching J, Arrowsmith E, Assikis V, Beer T, Berry W, Bolger G, Bryce A, Bubley G, Chatta G, Denmeade S, Deshpande H, Dorff T, Galsky M, George D, Giudice R, Glode M, Golshayan AR, Goodman O, Graff J, Green L, Green R, Haas N, Higano C, Hutson T, Kohli M, Liu G, May J, Mendelson D, Picus J, Pili R, Posadas E, Redfern C, Rettig M, Ryan C, Scholz M, Sharifi N, Sosman J, Srinivas S, Tagawa S, Twardowski P, Vaishampayan U, Wong YN; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97.

146. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, Alam M, Brown M, Clingan P, Costello A, Davis I, de Souza P, Horvath L, Inglis P, Lynch R, Mainwaring P, Marx G, Ng S, Nott L, Parnis F, Steer C, Van Hazel G, Wong S, Janetschek G, Loidl W, Marberger M, Luyten D, Machiels J, Renard V, Rottey S, Sautois B, Schöffski P, Schrijvers D, Van Aelst F, Werbrouck P, Wynendaele W, Cheng T, Chi K, Ellard S, Ernst S, Hotte S, Jancewicz M, Klotz L, Michels J, North S, Rajan R, Saad F, Wood L, Yadav S, Abadie S, Fizazi K, Fléchon A, Joly F, Kaplan R, Krakowski I, Oudard S, Rolland F, Zanetta S, Miller K, Pfister D, Stöckle M, Suttmann H, Wirth M, Faluhelyi Z, Salamon C, Wenczl M, Algeri R, Boni C, Cianci C, Conte P, Sternberg C, Villa E, Mulders P, Bird B, Breathnach O, McCaffrey J, McDermott R, O'Reilly S, **Bellmunt J**, Duran Martinez I, Font Pous A, Gallardo E, Germa Lluch J, Gil Bazo I, Gonzalez del Alba A, Mellado Gonzalez B, deBono J, Durkan G, Elliot P, Harland S, Hoskin P, James N, Jones R, Patterson H, Protheroe A, Staffurth J, O'Sullivan J, Waxman J, Aklilu M, Appelman L, Arrowsmith E, Assikis V, Baron A, Berry W, Burke J, Carney J, Chu L, Cohen N, Cosgriff T, Crane E, Curti B, Dakhil S, Denmeade S, Ferrari A, Flaig T, Gabrail N, Galsky M, George D, Goodman O, Gore I, Hahn N, Hainsworth J, Hamid O, Harris J, Hutson T, Iannotti N, Koletsky A, Lara P, Larson T, Logothetis C,

May J, McClean J, Modiano M, Montgomery R, Nordquist L, Picus J, Redfern C, Rettig M, Riggs S, Rosen P, Ryan C, Saleh M, Sarantopoulos J, Sartor A, Scher H, Scholz M, Segota Z, Sehpande H, Shore N, Showel J, Smith M, Tagawa S, Tan W, Tejwani S, Tjan-Wettstein V, Twardowski P, Vacirca J, VanVeldhuizen P, Vira M, Wong Y, Wu S, Yu E. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0.

147.**Bellmunt J**, Petrylak DP. New therapeutic challenges in advanced bladder cancer**.** Semin Oncol. 2012 Oct;39(5):598-607

148.Rescigno P, Buonerba C, **Bellmunt J**, Sonpavde G, De Placido S, Di Lorenzo G. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets**.** 2012 Dec;13(13):1676-86. (Editorial)

149.Merseburger AS, **Bellmunt J**, Jenkins C, Parker C, Fitzpatrick JM; European Treatment Practices Group. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Review. Erratum in: Oncologist. 2013;18(8):971. Oncologist. 2013;18(6):775.

150.Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Boyce A, Costello A, Davis I, Ganju V, Horvath L, Lynch R, Marx G, Parnis F, Shapiro J, Singhal N, Slancar M, Van Hazel G, Wong S, Yip D, Carpentier P, Luyten D, Rottey S, Van Aelst F, Cheng T, Chin J, Ellard S, Fradet Y, Gleave M, Joshua A, Klotz L, Martins H, North S, Abdel-Hamid S, Colombel M,Fléchon A, Haillot O, Joly F, Oudard S, Priou F, Raymond E, Albers P, Boegemann M, Gleissner J, Gschwend J, Hammerer P, Heidenreich A, Kuczyk M,Miller K, Oetzel R, Roigas J, Steuber T, Stöckle M, Wirth M, Papandreou C, Bracarda S, Marcello T, Sternberg C, Bangma C, de Reijke T, Arija J,**Bellmunt J,** Lopez R, Lopez-Brea M, Bjartell A, Damber J, Haggman M, Hellstrom M, Seke M, Brown J, Chowdhury S, Elliott T, Harland S, Innes H, James N, Jones R, Mazhar D, Paez E, Protheroe A, Staffurth J, Ahmann F, Andriole G, Arrowsmith E, Assikis V, Baron A, Berry W, Bubley G, Carney J, Chu L,Cosgriff T, Denmeade S, Deshpande H, Duchene D, Ferrari A, Frenkel E, Gabrail N, Garcia J, George D, Gomella L, Goodman O, Gore I, Gullo J,Hainsworth J, Hamid O, Hutson T, King D, Koh H, Koletsky A, Kudrik F, Lara P, Lyons R, Maranchie J, Modiano M, Nieva J, Nordquist L, Pinski J, Poiesz B, Polikoff J, Quinn D, Redfern C, Riggs S, Ryan C, Saleh M, Sartor A, Scholz M, Shore N, Srinivas S, Vaishampaya U, Vieweg J, Vira M, Vogelzang N,Wilding G, Wong Y, Belldegrun A, Kantoff PW, Carducci MA, Vogelzang NJ, Kelly WK, Auchus RJ, Meyers M, Rackoff W, Tran N, Yu M, Knoblauch R,Naini V, Matheny S, Maul S, Larsen J, Martin J, Wawda H, Goffredo D, Li J, Li S, Li B, Durve K, Morris MJ, Larson SM.; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48.

151.Procopio G, **Bellmunt J**, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer. 2013 Feb 5;108(2):311-8.

152.**Bellmunt J**. Tackling the Bone with Alpha Emitters in Metastatic Castration-resistant Prostate

Cancer Patients. Eur Urol. 2013 Feb;63(2):198-200.(Editorial).

153. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, **Bellmunt J**. Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. Eur Urol. 2013 Apr;63(4):717-23.

154. Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, **Bellmunt J**. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013 Apr;31(2):390-8.

155. Gallén M, Gallego R, **Bellmunt J**. Stage II disease, elderly patients, secondary neoplasms, and the MOSAIC trial. J Clin Oncol. 2013 Apr 20;31(12):1609.

156. de la Piedra C, Alcaraz A, **Bellmunt J**, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer. 2013 Jun 25;108(12):2565-72.

157. **Bellmunt J**, Fougeray R, Rosenberg JE, von der Maase H, Schutz FA, Salhi Y, Culine S, Choueiri TK. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013 Jun;24(6):1466-72.

158. Calvo E, Ravaud A, **Bellmunt J**. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. 2013 Jun;39(4):366-74.

159. Bracarda S, Montironi R, Porta C, Szczylic C, Bearz A, Cartenì G, **Bellmunt J**. The treating scenario in genitourinary oncology: what is new? Part 1. Future Oncol. 2013 Jun;9(6):797-801.

160. Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, **Bellmunt J**, Vogelzang NJ. Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep. 2013 Jun;14(3):174-83.

161. Bracarda S, Montironi R, Porta C, Szczylic C, Bearz A, Cartenì G, **Bellmunt J**. The treating scenario in genitourinary oncology: what is new? Part 2. Future Oncol. 2013 Jun;9(6):803-6.

162. **Bellmunt J**, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol. 2013 Jul;24(7):1730-40.

163. Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, **Bellmunt J**, Choueiri TK. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol

Hematol. 2013 Jul;87(1):80-9.

164. Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, **Bellmunt J**. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain. Expert Opin Drug Saf. 2013 Jul;12(4):455-63.

165. Sonpavde G, Galsky MD, **Bellmunt J**. A new approach to second-line therapy for urothelial cancer? Lancet Oncol. 2013 Jul;14(8):682-4.

166. Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, **Bellmunt J**; TUGAMO GROUP. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer. 2013 Jul 9;109(1):121-30.

167. Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, **Bellmunt J**, Matusik RJ, Rosenberg JE, Adam RM. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 2013 Jul;15(7):749-60.

168. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, **Bellmunt J**. Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. Eur Urol. 2013 Aug 28. pii: S0302-2838(13)00861-0.

169. López V, González-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, Vidal A, **Bellmunt J**, Heredero O, Sánchez-Carbayo M. Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med. 2013 Aug; 1(11):182.

170. Ravaud A, Gross-Goupil M, **Bellmunt J**. Combination therapy in metastatic renal cell cancer. Semin Oncol. 2013 Aug;40(4):472-81.

171. **Bellmunt J**, Pons F, Orsola A. Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol. 2013 Sep;23(5):466-71.

172. Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, **Bellmunt J**; BEVLiN Investigators. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol. 2013 Sep;24(9):2396-402.

173. Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, **Bellmunt J**, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013 Sep;24(9):2409-14.

174. Agarwal N, **Bellmunt J**, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ,

Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2013 Sep 28. pii: S1558-7673(13)00213-9.

175. Sternberg CN, Skoneczna IA, Castellano D, Theodore C, Blais N, Voog E, **Bellmunt J**, Peters F, Le-Guennec S, Cerbone L, Risse ML, Machiels JP. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85(4):208-15.

176. **Bellmunt J**, Teh BT, Tortora G, Rosenberg JE. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol. 2013 Oct;10(10):557-70.

177. Gallardo E, Arranz JÁ, Maroto JP, León LÁ, **Bellmunt J**. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. Crit RevOncol Hematol. 2013 Nov;88(2):357-67.

178. **Bellmunt J**, Leow JJ. Hyponatremia Associated with Worse Outcomes in Metastatic Renal Cell Cancer: A Potential Target for Intervention? Eur Urol. 2013 Nov 11. pii: S0302-2838(13)01195-0.

179. Harshman LC, Fougeray R, Choueiri TK, Schutz FA, Salhi Y, Rosenberg JE, **Bellmunt J**. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013 Nov 12;109(10):2548-53.

180. Paglino C, Procopio G, Sabbatini R, **Bellmunt J**, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C. A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. Anticancer Res. 2013 Nov;33(11):4999-5004.

181. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher Him, Alam M, Brown M, Clingan P, Costello A, Davis I, de Souza P, Glasgow A, Horvath L, Inglis P, Lynch R, Marx G, Ng S, Nott L, Nottage M, Parnis F,Underhill C, Van Hazel G, Wong S, Janetschek G, Loidl W, Marberger M, Luyten D, Machiels J, Renard V, Rottey S, Sautois B, Schöffski P, Schrijvers D, Van Aelst F, Werbrouck P, Wynendaele W, Ernst S, Hotte S, Jancewicz M, Klotz L, Michels J, Rajan R, Wood L, Abadie S, Joly F, Kaplan R,Krakowski I, Oudard S, Rolland F, Zanetta S, Miller K, Pfister D, Stöckle M, Suttmann H, Wirth M, Salamon C, Wenczl M, Algeri R, Boni C, Conte P,Cerbone L, Villa E, Mulders P, Bird B, Breathnach O, Janku F, McCaffrey J, McDermott R, **Bellmunt J**, Duran I, Lluch J, Durkan G, Elliot T, Hoskin P, James N, Protheroe A, O'Sullivan J, Waxman J, Appelman L, Arrowsmith E, Assikis V, Baron A, Berry W, Burke J, Carney J, Chu L, Cohen N, Cosgriff T,Crane E, Curti B, Dakhil S, Deshpande H, Denmeade S, Yearly activity and participation in the BCAN: Bladder Cancer Advocacy Network. This includes member of the Evaluation Committee of the BCAN-Young Investigator Award, Gabrail N, Galsky M, George D, Gore I, Hahn N, Hamid O, Harris J, Kelly W, Koletsky A, Lara P, Larson T, McClean J, Modiano M, Montgomery R, Nordquist L, Picus J, Redfern C, Rettig M, Riggs S, Rosen P, Sarantopoulos J, Sartor A,Segota Z, Shore N, Showel J, Smith M, Tagawa S, Tejwani S, Tjan-Wettstein V, Twardowski P, Vacirca J, VanVeldhuizen P, Vira M, Wong Y, Wu S, Yu E.; COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013 Nov; 49(17):3648-57.

182. Pond GR, Agarwal N, **Bellmunt J,** Choueiri TK, Qu AQ, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, di Lorenzo G, Sternberg CN, Mehta AN, Sonpavde G. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. 2013 Nov 13.

183. Stein A, **Bellmunt J,** Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. Eur Urol. 2013 Dec;64(6):994-1002.

184. Stein A, **Bellmunt J**, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. Eur Urol. 2013 Dec;64(6):994-1002.

185. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, **Bellmunt J,** Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1307-16.

186. Rini BI, **Bellmunt J,** Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial. J Clin Oncol. 2013 Dec 2. [Epub ahead of print] PubMed PMID: 24297945.

187. Pond GR, **Bellmunt J,** Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer. 2013 Dec;11(4):495-500.

188. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, **Bellmunt J**, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan;44(1):5-16.

189. Pons F, **Bellmunt J**. Sunitinib malate in the treatment of urothelial cancer. Expert Opin Investig Drugs. 2014 Jan;23(1):115-24.

190. Prior C, Perez-Garcia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, **Bellmunt J**, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martinez E, Moreno F, Font A, Calvo A. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One, 2014 Jan 24; 9 (1): e86263.

191. Guancial EA, **Bellmunt J**, Yeh S, Rosenberg JE, Berman DM. The evolving understanding of

microRNA in bladder cancer. Urol Oncol. 2014 Jan;32(1):41.e31-40.

192. Nadal R, Taplin ME, **Bellmunt J**. Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. Future Oncol. 2014 Feb;10(3).

193. Nadal R, **Bellmunt J**. New treatments for bladder cancer: when will we make progress? Curr Treat Options Oncol. 2014 Mar;15(1):99-114.

194. Rini BI, **Bellmunt J**, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol. 2014 Mar 10;32(8):752-9.

195. **Bellmunt J**, Leow JJ. Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? Eur Urol. 2014 Apr;65(4):731-2.

196. Riester M, Werner L, **Bellmunt J**, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 1;20(7):1873-83.

197. Castellano DE, **Bellmunt J**, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen. Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67.

198. Calvo E, Grünwald V, **Bellmunt J**. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy**.** Eur J Cancer. 2014 May;50(7):1321-9. doi: 10.1016/j.ejca.2014.02.007. Epub 2014 Mar 1.

199. Fitzpatrick JM, **Bellmunt J**, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel**.** Eur J Cancer. 2014 Jun;50(9):1617-27.

200. Choueiri TK, Jacobus S**, Bellmunt J**, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94.

201. Montgomery B, Kheoh T, Molina A, Li J, **Bellmunt J**, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. Eur Urol. 2014 Jul 10. pii: S0302-2838(14)00616-2.

202. Murta-Nascimento C, Romero AI, Sala M, Lorente JA, **Bellmunt J**, Rodero NJ, Lloreta J, Hospital A, Burón A, Castells X, Macià F. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. Eur J Cancer Prev. 2014 Jul 29.

203. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33.

204. Leow JJ, Chang SL, **Bellmunt J**. Reply from authors re: Cora N. Sternberg, Richard Sylvester. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer**.** Eur Urol 2014;66:55-6. Eur Urol. 2014 Jul;66(1):57-8.

205. **Bellmunt J**, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Chouieri TK. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Eur J Cancer. 2014 Aug; 12(4) : 262-9.

206. **Bellmunt J**, Pons F, Foreshew A, Fay AP, Powles T, Porta C, Bracarda S, Lampron ME, Cerbone L, Sternberg CN, Hutson TE, Choueiri TK. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. Clin Genitourin Cancer. 2014 Aug;12(4):262-9.

207. **Bellmunt J**, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo, B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE. Identification of ALK gene alterations in urothelial carcinoma. PLoS One. 2014 Aug 1;9(8).

208. Guancial EA, Werner L, **Bellmunt J**, Bamias A, Choueiri TK, Ross R, Schutz FA, Park RS, O'Brien RJ, Hirsch MS, Barletta JA, Berman DM, Lis R, Loda M, Stack EC, Garraway LA, Riester M, Michor F, Kantoff PW, Rosenberg JE. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug;3(4):835-44.

209. **Bellmunt J**, Leow JJ, Martin-Doyle W. Unveiling the surgical risk associated with neoadjuvant chemotherapy in bladder cancer. BJU Int. 2014 Aug;114(2):163-4.

210. **Bellmunt J**, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist. 2014 Sep;19(9):917-8.

211. Leow JJ, Reese SW, Jiang W, Lipsitz SR, **Bellmunt J**, Trinh QD, Chung BI, Kibel AS, Chang SL. Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep;66(3):569-76.

212. Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, **Bellmunt J**. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014 Sep;66(3):529-41.

213. Sonpavde G, Pond GR, Fougeray R, **Bellmunt J**. Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU Int. 2014 Sep 5.

214. Agarwal N, Di Lorenzo G, Sonpavde G, **Bellmunt J**. New agents for prostate cancer. Ann Oncol.

2014 Sep;25(9):1700-9.

215. Fizazi K, Abrahamsson PA, Ahlgren G, **Bellmunt J**, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe. Eur Urol**.** 2014 Sep 10. pii: S0302-2838(14)00880-X.

216. Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, **Bellmunt J**, Choueiri TK. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov;92(2):123-32.

217. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, **Bellmunt J**, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014 Nov;25(11):2178-84.

218. Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, **Bellmunt J**, Choueiri TK. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer. 2014 Nov 7. pii: S1558-7673(14)00235-3.

219. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, **Bellmunt J**, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27;515(7528):558-62.

220. Sonpavde G, **Bellmunt J**, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.

221. Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, **Bellmunt J**, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol. 2014 Dec 20;32(36):4171-2.

222. Fay AP, Albiges L, **Bellmunt J**. Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015 Feb;15(2):151-6

223. Gore ME, **Bellmunt J**, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, Lewis S, Kirpekar S. Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). Eur J Cancer. 2014 Dec;50(18):3153-60.

224. Porta C, Levy A, Hawkins R, Castellano D, **Bellmunt J**, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014 Dec;3(6):1517-26.

225. Orsola A, **Bellmunt J**. The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan;67(1):30-2.

226. Merseburger AS, Scher HI, **Bellmunt J**, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K,

Hirmand M, Franks B, Haas GP, de Bono J, de Wit R. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015 Jan;115(1):41-9.

227. Fay AP, Signoretti S, Callea M, Teló GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, **Bellmunt J**, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015 Feb 17;3:3.

228. **Bellmunt J**, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Feb 26.

229. Pond GR, **Bellmunt J**, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015 Feb;13(1):71-9.

230. Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, Mullane SA, Leow JJ, Barletta JA, **Bellmunt J**, Morote J. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer**.** 2015 Feb 3;112(3):468-74.

231. Martin-Doyle W, Leow JJ, Orsola A, Chang SL, **Bellmunt J**. Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. J Clin Oncol**.** 2015 Feb 20;33(6):643-650.

232. Leow JJ, Orsola A, Chang SL, **Bellmunt J**. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015 Feb 18. pii: S0305-7372(15)00027-4.

233. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2): 152-60.

234. Fuertes J, Montagut C, Bullich S, Coma MI, Mestre-Fusco A, Suárez-Piñera M, Trampal C, **Bellmunt J**. Incidental focal uptake in colorectal location on oncologic FDG PET and PET/CT studies: Histopathological findings and clinical significances. Rev Esp Med Nucl Imagen Mol. 2015 Mar-Apr;34(2):95-101.

235. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, **Bellmunt J**, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5**.**

J Clin Oncol. 2015 Mar 1;33(7):723-31..

236. Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, **Bellmunt J**, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol**.** 2015 Mar 2. pii: S1470-2045(15)70025-2.

237. **Bellmunt J**, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol. 2015 Apr;26(4):812-7

238. Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, **Bellmunt J**, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative Cisplatin-based therapy. Clin Genitourin Cancer. 2015 Apr;13(2):178-84.

239. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, **Bellmunt J**. Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. Clin Genitourin Cancer. 2015 Apr;13(2):185-92.

240. Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, **Bellmunt J**, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 9; 15: 242.

241. Leow JJ, Fay AP, Mullane SA, **Bellmunt J**. Perioperative therapy for muscle invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2): 301-318.

242. Sonpavde G, Jones BS, **Bellmunt J**, Choueiri TK, Sternberg CN. Future Directions and targeted therapies in bladder cancer. Hematol Oncol North Am. 2015 Apr; 29(2): 361-76.

243. **Bellmunt J**. Bladder Cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2); xiii-xiv.

244. Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, **Bellmunt J**, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res. 2015 May 1;21(9):2157-66.

245. Leow JJ, Reese S, Trinh QD, **Bellmunt J**, Chung BI, Kibel AS, Chang SL. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int. 2015 May; 115(5): 713-21.

246. Sonpavde G, **Bellmunt J**. Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? Oncologist. 2015 May; 20(5): 461-3.

247. **Bellmunt J**, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME,

Choueiri TK, Van Allen E, Rosenberg J. Somatic copy number abnormalities and mutations in P3K/AKT/mTOR pathway have prognostic signficance for overall survival in platinum treated locally advanced or metastatic urothelial tumors. PLoS One. 2015 June 3; 10(6); e0124711.

248. Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan Un, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, **Bellmunt J**, Rosenberg JE, Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug 1; 121(15): 2586-93.

249. Sonpavde G, Pond GR, Choueiri TK, Mullane S, Neigisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, **Bellmunt J**. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol. 2015 Aug 8; pii S0022-5347(15)04605-4. [Epub ahead of print].

250. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, **Bellmunt J**. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2015 Aug 17; 7(111): 4605-4.

251. Cole AP, Dalela D, Hanske J, Mullane SA, Choueiri TK, Meyer CP, Nguyen PL, Menon M, Kibel AS, Preston MA, **Bellmunt J**, Trinh QD. Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. Urol Oncol. 2015 Aug 25; pii S1078-1439(15)00358-0. [Epub ahead of print].

252. **Bellmunt J**, Orsola A, Sonpavde G. Precision and predictive medicine in urothelial cancer; are we making progress? Eur Urol. 2015 Oct; 68(4): 547-9.

253. Fay AP, **Bellmunt J**. Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? BJU Intl. 2015 Oct; 116(4):500-1.

254. Sonpavde G, **Bellmunt J**. Docetaxel for castration-sensitive prostate cancer: wrapping up unfinished business? Eur Urol. 2015 Oct 20; pii SO302-2838(15)01003-9. [Epub ahead of print].

255. Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, **Bellmunt J**, Necchi A. The impact of adding taxanes to gemcitabine and platinum chemotherapy for the first-line therapy of advanced or metastatic urothelial cancer: a systematiac review and meta-analysis. Eur Urol. 2015 Oct 20; piiS0302-2838(15)00974-4. [Epub ahead of print].

256. **Bellmunt J**, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: post-hoc analysis of randomised phase 3 studies. Eur Urol. 2015 Oct 24; pii S0302-2838(15)01002-7. [Epub ahead of print].

257. Sonpavde G, Pond GR, **Bellmunt J**. Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. Eur Urol. 2016 Apr;69(4):644-5. doi:

10.1016/j.eururo.2015.09.015.

258. Raggi D, Miceli R, Sonpavde G, Giannatempo P, Mariani L, Galsky MD, **Bellmunt J**, Necchi A. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016 Jan;27(1):49-61. doi: 10.1093/annonc/mdv509.

259. Sonpavde G, **Bellmunt J**. Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? Eur Urol. 2016 Apr;69(4):574-5. doi: 10.1016/j.eururo.2015.10.022.

260. Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, **Bellmunt J**, Necchi A. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Apr;69(4):624-33. doi: 10.1016/j.eururo.2015.09.051.

261. **Bellmunt J**, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021.

262. de Velasco G, Krajewski KM, Albiges L, Awad MM, **Bellmunt J**, Hodi FS, Choueiri TK. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197.

263. Harshman LC, Preston MA, **Bellmunt J**, Beard C. Diagnosis of Bladder Carcinoma: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec;8(4):677-85. doi: 10.1016/j.path.2015.07.004. Review.

264. De Santis M, Wiechno PJ, **Bellmunt J**, Lucas C, Su WC, Albiges L, Lin CC, Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl WC, Retz MM, Vaissière N, Culine S. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016 Mar;27(3):449-54. doi: 10.1093/annonc/mdv609.

265. Chi KN, Kheoh T, Ryan CJ, Molina A, **Bellmunt J**, Vogelzang NJ, Rathkopf DE, Fizazi K, Kantoff PW, Li J, Azad AA, Eigl BJ, Heng DY, Joshua AM, de Bono JS, Scher HI. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016 Mar;27(3):454-60. doi: 10.1093/annonc/mdv594.

266. van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, **Bellmunt J**, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2016 May;69(5):802-20. doi: 10.1016/j.eururo.2015.11.023.

267. Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, **Bellmunt J**, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of

Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 Aug;14(4):e299-305. doi: 10.1016/j.clgc.2015.12.008.

268. Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, **Bellmunt J**. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 Aug;14(4):352-9. doi: 10.1016/j.clgc.2015.12.029.

269. Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, de Velasco G, Tyburczy ME, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, **Bellmunt J**, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 May 15;22(10):2445-52. doi: 10.1158/1078-0432.CCR-15-2631.

270. Nadal R, **Bellmunt J**. The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncol. 2016 Mar;12(5):607-16. doi: 10.2217/fon.15.351.

271. Mullane SA, **Bellmunt J**. Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. Eur Urol. 2016 Sep;70(3):e71. doi: 10.1016/j.eururo.2016.01.036.

272. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, **Bellmunt J**, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4.

273. Gakis G, Schubert T, Alemozaffar M, **Bellmunt J**, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2016 Apr 4.

274. Sonpavde G, **Bellmunt J**. Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol. 2016 Jun;13(6):306-7. doi: 10.1038/nrurol.2016.69.

275. Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, **Bellmunt J**, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med. 2016 Jun;22(6):685-91. doi: 10.1038/nm.4085.

276. McKay RR, De Velasco G, Werner L, **Bellmunt J**, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer. 2016 Aug 1;122(15):2389-98. doi: 10.1002/cncr.30056.

277. Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, **Bellmunt J**. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2016 May 12. pii: S1558-7673(16)30112-4. doi: 10.1016/j.clgc.2016.05.001.

278. Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F, Hanna N, Meyer CP, Kibel AS, Lipsitz SR, Nguyen PL, **Bellmunt J**, Choueiri TK, Trinh QD. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 Jun 6. pii: JCO667352.

279. Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, **Bellmunt J**. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep. 2016 Jun 10;6:27702. doi: 10.1038/srep27702.

280. Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, **Bellmunt J**, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Jun 16. doi: 10.1001/jamaoncol.2016.1056.

281. Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, **Bellmunt J**, Sonpavde G. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer. 2016 May 27. pii: S1558-7673(16)30129-X. doi: 10.1016/j.clgc.2016.05.003.

282. **Bellmunt J**, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer. 2016 Jun 28;115(1):12-9. doi: 10.1038/bjc.2016.146.

283. **Bellmunt J**, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016 Mar;14(1):1-20. doi:10.1016/j.ejcsup.2016.01.001.

284. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, **Bellmunt J**, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bl Cancer. 2016 Apr 27;2(2):165-202.

285. Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, **Bellmunt J**, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw. 2016 Jul;14(7):820-4.

286. Vogelzang NJ, Fizazi K, Burke JM, De Wit R, **Bellmunt J**, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol.

2016 Aug 10. pii: S0302-2838(16)30467-5. doi: 10.1016/j.eururo.2016.07.051.

287. de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, **Bellmunt J**, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study. JAMA Oncol. 2016 Aug 25. doi: 10.1001/jamaoncol.2016.3000.

288. Mottet N, **Bellmunt J**, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016 Aug 25. pii: S0302-2838(16)30470-5. doi: 10.1016/j.eururo.2016.08.003.

289. Cornford P, **Bellmunt J**, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30469-9. doi: 10.1016/j.eururo.2016.08.0024:

290. Ramos JD, Casey MF, Bamias A, De Giorgi U, **Bellmunt J**, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY; Retrospective International Study of Cancers of the Urothelium (RISC) Investigators. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin Appl Thromb Hemost. 2016 Sep 16. pii: 1076029616668405.

291. Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, **Bellmunt J**. Outcomes of advanced urothelial carcinoma patients following discontinuation of Programmed Death (PD)-1 or PD-Ligand (L)-1 inhibitors. BJU Int. 2016 Oct 4. doi: 10.1111/bju.13674.

292. Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, **Bellmunt J**, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L; RISC Investigators.. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2016 Oct 8. pii: S0302-2838(16)30682-0. doi: 10.1016/j.eururo.2016.09.042.

293. Mullane SA, **Bellmunt J**. Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol. 2016 Nov;26(6):556-63. doi: 10.1097/MOU.0000000000000337.

Non-peer reviewed scientific or medical publications/materials in print or other media

1. Solé LA, Albanell J, **Bellmunt J**. *Neoplasia trofoblástica gestacional* (Gestational Trophoblastic Neoplasia). In: M. Gonzalez Baron, editor. *Oncología Clínica*. Madrid; Interamericana Mc Graw Hill, 1992. p. 251-262.

2. Solé-Calvo LA, **Bellmunt J**. *Historia natural y estadiaje de los sarcomas de partes blandas* (Natural history and staging of soft tissue sarcomas). In: E. Diaz Rubio, editor. *Revisiones en Cancer* (Cancer Revisions) -*2*. Madrid; Ed Aran, 1992. p. 899-904.

3. Solé LA, **Bellmunt J**, Albanell J. *Indicaciones del interferón en oncología* (Interferon indications in Oncology). In: E. Diaz Rubio, editor. *Controversias en Oncología (*Controversies in Oncology*)*. Barcelona: Ed. Doyma S.A.,1993. p.93-106,

4. Morote Robles J, **Bellmunt Molins J**. *Cáncer de próstata: resistencia a la hormonoterapia.* (Prostate cáncer; hormone resistance). In: J Fernando Jiménez Cruz y CD Vera Donoso, editors. *Diagnostico y tratamiento de la recidiva en los tumores urológicos (*Diagnosis and treatment of recurrence in urological cancers). Madrid; Grupo Biblioteca Aula Médica, 1997. p. 163-179.

5. Solé LA, **Bellmunt J**, Albanell J. *Neoplasia gestacional trofoblástica* (Gestational Trophoblastic Neoplasia). In Gonzalez Baron M, Ordoñez A, Feliu J, Zamora P, espinosa E, De Castro J editors *Oncologia Clinica; Patologia Especial* (Clinical Oncology; Special Pathology)). Editorial Interamericana Mc Graw Hill, Madrid; 1998. p.341-352.

6. **Bellmunt J**, Lorente JA, Maldonado J, Morote J. *Cancer de Próstata (Prostate Cancer)*. In: H. Cortés-Funes, E. Diaz-Rubio, J Garcia-Conde, JR Germà Lluch, V Guillem, JJ López López, JA Moreno Nogueiray, G Peraz Manga, editors. *Oncología Médica* (Medical Oncology). Barcelona; Biblioteca Aula Médica, 1999. p 639-659.

7. **Bellmunt J**. *Tratamiento quimioterápico en las neoplasias hepatobiliopancreaticas (*Chemotherapy in hepatobiliar carcinomas). In: C. Margarit, editor. *Transplante hepático y cirugía hepato-bilio-pancreática*. (Hepatic Transplant and hepato-biliar-pancreatic surgery). Madrid; DRUG Farma, 2000. p 313-321.

8. **Bellmunt, J.** co-author. *Documentos de Consenso en Oncología. Cáncer de Vejiga*. (Consensus documents in Oncology. Bladder Cancer). In: A. Abad, P. Gascon, E- Díaz-Rubio editors. *Guía Práctica de Tumores Sólidos* (Practical Guidelines for Solid Tumors). Madrid; Nova Sidonia Oncología, 2001. p.278-286..

9. **Bellmunt, J**. *Cancer de vejiga* (Bladder Cancer). In*:* A. Abad, P. Gascon, E- Díaz-Rubio editors, In*: Guía Práctica de Tumores Sólidos* (Practical Guideline of Solid Tumors). Madrid; Nova Sidonia Oncología, 2004. p. 177-199.

10. **Sella A, Bellmunt J.** Treatment of Metastatic Cancer. In Seth P. Lerner, Mark Schoenberg and Cora Sternberg, co-editors. Bladder Cancer Textbook. London; Martin Dunitz & Parthenon Publishing, 2004. p. 671-682.

11. Palou J, Banus JM, **Bellmunt J**, Carulla J, Egido R. Wilms' tumor in an adult patient. Urol Int. 1988;43(6):349-51.

12. Montalban J, Molins A, Fernandez JL, Romero F, **Bellmunt J**, Alvarez J, Codina Puiggros A. Solitary cerebellar metastases: a clinical neuro-radiological study. Neurologia. 1988; 3(1):3-8.

13. **Bellmunt J**, Navarro M, Hidalgo R, Sole LA. Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori. 1988; 74(3):329-31.

14. Navarro M, Almirante B, **Bellmunt J**, Jolis L. Fatal septic thrombophlebitis due to Salmonella enteritidis. Eur J Clin Microbiol Infect Dis. 1989; 8(1):82-3.

15. Prats J, **Bellmunt J**, Calvo MA, Sarrias F, Toran N. Orbital metastasis, by transitional cell

carcinoma of the bladder. Int Urol Nephrol. 1989; 21(4):389-92.

16. Morales S, Navarro M, **Bellmunt J**, Jolis L. Acromegaly and lung cancer. Rev Clin Esp. 1989; 184(6):337-8.
17. **Bellmunt J**, Allende E, Navarro M, Morales S, Sans M, Jolis L, Garcia AA, Rubio D. Epithelioid hemangioendothelioma of the liver with myocardial metastases. Jpn J Clin Oncol. 1989; 19(2):153-8.
18. Navarro M, Morales S, **Bellmunt J**, Jolis L. Metachronic squamous carcinoma of the tonsils to microcytic carcinoma of the esophagus. Med Clin (Barc). 1990; 94(2):77-8.
19. **Bellmunt J**, Morales S, Allende E, Sole Calvo LA. Epithelioid hemangioendothelioma of the liver. Med Clin (Barc). 1990; 94(5):198.
20. Albanell J, Salud A, **Bellmunt J**, Espanol T, Morales S, Garcia-Bragado F, Sole-Calvo LA. Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult. Med Clin (Barc). 1990; 94(5):184-6.
21. Navarro M, Felip E, Garcia L, **Bellmunt J**, Jolis L, Morales S, Rubio D. Addison's disease secondary to prostatic carcinoma. A case report. Tumori. 1990; 76(6):611-3.
22. Felip E, Rovirosa MA, Salud A, Capdevila F, **Bellmunt J**, Giralt J. Orbital metastases from transitional-cell cancer of the urinary bladder. Urol Int. 1991; 46(1):82-4.
23. Salud A, Porcel JM, Vidal-Pla R, **Bellmunt J**. Pulmonary metastasising benign leiomyoma evolving to chronic respiratory failure. Med Clin (Barc). 1997; 109(9):358.
24. Ribas A, Albanell J, **Bellmunt J**, Sole-Calvo LA. Re: Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst. 1997; 89(5):395-6.
25. Margarit C, Escartin A, **Bellmunt J**, Allende E, Bilbao I. Peripheral cholangiocarcinoma: results of surgical treatment. Gastroenterol Hepatol. 2006; 29(4):215-23.
26. Beck J, **Bellmunt J**, Escudier B. Long-term stable disease in metastatic renal cell carconoma: sorafenib sequenced to sunitinib and everolimus: a case study. Med Oncol. 2011 Dec;28(4):1379-83.
27. Katz L, Choueiri TK, **Bellmunt J.** C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. BJU Int. 2010 Nov;106(9):1249-50.
28. Wagner M, **Bellmunt J**, Boutros C, Bonardel G, Loriot Y, Albiges L, Massard C, Fizazi K. False Positive 2-(18)Fluroro-deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Disseminated Seminoma and Post-Chemotherapy: Residual Masses. Clin Genitourin Cancer. 2012 Sep 12. doi:pii:S1558-7673(12)00169-3. 10.1016/j.clgc.2012.06.006.

Clinical Guidelines and Reports

1. **Bellmunt J**. Co-author. International Consensus in Urological Diseases (ICUD). Guidelines. Urology; 2005.
2. **Bellmunt J**, Albiol S, Kataja V; ESMO Guidelines Working Group. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008 May;19 Suppl 2:ii47-8.

3. De Reijke TM, **Bellmunt J**, van Poppel H, Marreaud S, Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer**.** Eur J Cancer. 2009 Mar;45(5):765-73.

4. **Bellmunt J**, Albiol S, Kataka V, ESMO Guidelines Working Group. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:79-80.

5. **Bellmunt J**, Négrier S, Escudier B, Awada A, Aapro M; SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009 Jan;69(1):64-72.

6. **Bellmunt J**, Calvo E, Castellano D, Climent MA, Esteban E, García del Muro X, González-Larriba JL, Maroto P, Trigo JM. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol. 2009 Mar;63 Suppl 1:S1-13.

7. **Bellmunt J**, Orsola A, Maldonado X, Kataja V; ESMO Guidelines Working Group. Bladder Cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up**.** Ann Oncol. 2010 May;21 Suppl 5v134-6.

8. Heidenreich A, **Bellmunt J**, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schimd HP, Van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease**.** Eur Urol. 2011 Jan; 59(1):61-71.

9. Mottet N, **Bellmunt J**, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2011 Apr;59(4):572-83.

10. **Bellmunt J**, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V; ESMOGuidelines Working Group. Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi45-9.

11. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, **Bellmunt J**. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017.

12. Sternberg CN, **Bellmunt J**, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-Neoadjuvant and Adjuvant Settings. Eur Urol. 2013 Jan;63(1):58-66. doi: 10.1016/j.eururo.2012.08.010.

13. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V Parker C, **Bellmunt J**, Berthold D, Bill-Axelson A, Carlsson S, Daugaard G, De Meerleer G,de Reijke T, Dearnaley D, Fizazi K, Fonteyne V, Gillessen S,Heinrich D, Horwich A, Hogosson J, Kataja V, Kwiatkowski M, Nilsson S, Padhani A, Papandreou C, Parker C, Roobol M, Sella A, Valdagni R, Van der Kwast T, Verhagen P, Wiegel T; Panel Members; European Society for Medical Oncology. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013 May;24(5):1141-62.

14. Heidenreich A, Bastian PJ, **Bellmunt J**, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014 Jan;65(1):124-37.

15. Heidenreich A, Bastian PJ, **Bellmunt J**, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol. 2014 Feb;65(2):467-79.
16. **Bellmunt J**, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8.
17. **Bellmunt J**, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014 Dec;16(12):1043-50.

Thesis

Bellmunt, J. Lymfocite subpopulations in BAL (bronco-alveolar lavage) of smokers vs. non-smokers [dissertation] Barcelona (Spain); Autonomous University of Barcelona; 1989.

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Dreicer R, Agus DB, **Bellmunt J**, De Bono JS, Petrylak DP, Tejura B, Shi Y, Fizazi K: A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. ASCO Meeting Abstracts 2012;30:TPS4693.
2. Fougeray R, Choueiri TK, Pons F, Schutz FAB, Salhi Y, Rosenberg JE, **Bellmunt J**: Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine. ASCO Meeting Abstracts 2012;30:e15007.
3. Macia S, Garcia-Donas J, Font Pous A, Domenech M, Garcia del Muro X, Mellado B, Puente J, Arranz Arija JA, Climent Duran MA, Lainez Milagro N, Perez-Gracia JL, Gonzalez del Alba A, Villa Guzman JC, Perez-Valderrama B, Echaburu JV, Bonfill T, Leon Mateos L, Morales-Barrera R, Castellano DE, **Bellmunt J**, Spanish Oncology Genitourinary G: Vinflunine maintenance therapy versus best supportive care (BSC) after platinum combination in advanced bladder cancer: A phase II, randomized, open-label study (MAJA study)--SOGUG 2011-02. ASCO Meeting Abstracts 2012;30:TPS4674.
4. Duran I, Montagut C, Calvo E, Galtes S, Navarrete A, Rodriguez-Pascual J, Hidalgo M, Rodriguez-Moreno JF, Cubillo A, Garcia A, Sanchez L, Barbas C, Viqueira A, **Bellmunt J**: Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel. ASCO Meeting Abstracts 2012;30:250.
5. Martin Liberal J, Maroto JP, Mellado B, Ferrer F, Sancho G, Rovirosa A, Vigues F, Palou J, Ribal MJ, **Bellmunt J**, Garcia del Muro X: Phase I trial of sorafenib with concurrent radiotherapy (RT) in patients with invasive bladder cancer treated with bladder-sparing intent: A Spanish Oncology Genitourinary Group study. ASCO Meeting Abstracts 2012;30:270.
6. Guancial EA, Werner L, Stack E, Lis R, Signoretti S, Loda M, Gallardo E, Rojo F, Lloreta J, Regan MM, Park R, O'Brien R, Berman DM, **Bellmunt J**, Rosenberg JE: Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. ASCO Meeting Abstracts 2012;30:291.

7. Pond G, Sonpavde G, Choueiri T, Qu A, Vaughn D, Fougeray R, Niegisch G, Albers P, Wong Y, Ko YJ, Sridhar S, Galsky M, Petrylak D, Beer T, Stadler WM, O'Donnell P, Sternberg C, Rosenberg J, **Bellmunt J**: Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. ASCO Meeting Abstracts 2012; 30: 4522.
8. **Bellmunt J**, Werner L, Guix M, Guancial EA, Schutz F, O'Brien R, Stack E, Loda M, Berman D, Hirsch M, Signoretti S, Gallardo E, Rojo F, Ross R, Kantoff P, Choueiri T, Rosenberg J: PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target. ASCO Meeting Abstracts 2012; 30: 4582.
9. Maughan B, Boucher K, Agarwal N, Choueiri T, Qu A, Vogelzang N, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar S, Galsky M, Petrylak D, Vaishampayan U, Beer T, Sternberg C, Rosenberg J**, Bellmunt J**, Sonpavde G: Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).ASCO Meeting Abstracts 2012; 30: 4525.
10. Galsky M, Chowdhury S, **Bellmunt J**, Wong YN, Recine F, Pal SK, Moshier E, Ladoire S, De Giorgi U, Yu E, Niegisch G, Crabb S, Mardones M, Necchi A, Golshayan AR, Bamias A, Mano R, Harshman LC, Powles T, Rosenberg J: Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC). ASCO Meeting Abstracts 2013; 31: 4525.
11. Fizazi K, Heidenreich A, Daugaard G, **Bellmunt J**, Germann N, Chetaille E: Randomized, double-blind, placebo-controlled proof of concept study of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who experience response or stabilization during first-line docetaxel chemotherapy.ASCO Meeting Abstracts 2013; 31: TPS5098.
12. Collette S, Sylvester R, **Bellmunt J**, Mead G, Kerst J, Leahy MG, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna IA, De Wit R, De Santis M: Prognostics factors in previously untreated urothelial cancer patients ineligible for cisplatin-based chemotherapy: An external validation of the Bajorin risk groups.ASCO Meeting Abstracts 2013; 31: 4529.
13. Martin AL, **Bellmunt J**, Maroto J, Gallardo E, Brea ML, Perez-Gracia JL, Castellano D, Valverde CM, Bezares S, Calvo E, Paz-Ares L: Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II.ASCO Meeting Abstracts 2013; 31: 4550.
14. Sonpavde G, Pond GR, Agarwal N, Choueiri T, Qu A, Fougeray R, Salhi Y, Vaughn D, James ND, Niegisch G, Albers P, Galsky M, Wong YN, Stadler WM, O'Donnell P, Vogelzang N, Sridhar S, Ko YJ, Sternberg C, **Bellmunt J**: Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC).ASCO Meeting Abstracts 2013; 31: 4524.
15. Montgomery R, Kheoh TS, Molina A, Li J, **Bellmunt J**, Ryan C, Tran N, Loriot Y, Efstathiou E, Scher H, De Bono JS: Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). ASCO Meeting Abstracts 2013; 31: 5014.
16. Chi K, Kheoh TS, Ryan C, Molina A, **Bellmunt J,** Vogelzang N, Rathkopf D, Fizazi K, Kantoff P, Li J, De Bono JS, Scher H: A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.ASCO Meeting Abstracts 2013; 31: 5013.
17. Guancial E, Werner L, **Bellmunt J**, Nikitas N, Stack E, Lis R, Signoretti S, Loda M, Regan M, Park R, O'Brien R, Berman D, Bamias A, Rosenberg J: Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).Genitourinary Cancer Symposium Abstracts 2013; 31: 260.

18. Bambury R, Iyer G, Riester M, Werner L, Schultz N, Stack E, Park R, Loda M, Ostrovnaya I, Kantoff P, Bajorin D, Solit D, Michor F, **Bellmunt J**, Rosenberg J: Peroxisome proliferator-activated receptor gamma (*PPARG*) gene amplifications in urothelial carcinoma (UC).Genitourinary Cancer Symposium Abstracts 2013; 31: 279.
19. Bambury R, Riester M, **Bellmunt J**, Stack E, Werner L, Park R, Iyer G, Loda M, Kantoff P, Michor F, Rosenberg J: Genomic characterization of metastatic urothelial carcinoma.Genitourinary Cancer Symposium Abstracts 2013; 31: 247.
20. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, **Bellmunt J**, Petrylak DP, Lee C, Tejura B, Borgstein NG, Dreicer R: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.ASCO Meeting Abstracts 2014; 32; 5042.
21. Sonpavde G, **Bellmunt J**, Rosenberg J, Bajorin D, Regazzi AM, Choueiri T, Qu A, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Wong YN, Sridhar S, Ko YJ, Milowsky M, Galsky M, Pond GR: Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.ASCO Meeting Abstracts 2014; 32; 4514.
22. Leow J, Martin-Doyle W, Lim V, Fay AP, Albiges L, Trinh QD, Sun M, Kaymakcalan M, **Bellmunt J**, Chang S, Choueiri T: Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.ASCO Meeting Abstracts 2014; 32: e15558.
23. De Santis M, Wiechno P, Lucas C, Su WC, Albiges L, Lin CC, **Bellmunt J,** Senkus-Konefka E, Flechon A, Mourey L, Necchi A, Loidl W, Morand M, Burillon JP, Fougeray R, Culine S: Feasibility and activity of two vinflunine (VFL)-based combinations as first-line chemotherapy (CT) in CDDP-unfit patients (pts) with advanced urothelial carcinoma (UC): VFL-gemcitabine (GEM) or VFL-CBDCA in a randomized international phase II trial (JASINT).ASCO Meeting Abstract 2014; 32: 4534.
24. Montagut C, Bellosillo C, Gonzalez I, Martinez A, Dalmases A, Iglesias M, Vidal J, Salido M, Garcia M, Busto M, Aguilar G, Moragon E, Espinet B, Serrano S, Rovira A, **Bellmunt J**, Albanell J: Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer.ASCO Meeting Abstract 2014; 32: 3526.
25. Gonzalez I, Castellano D, Esteban E, Arnillas QP, Munarriz J, Balea BC, Garcia-Bueno JM, Leon MLV, Laínez N, Rubio G, Santander C, Buron JDC, Sanchez JG, Martin A, Lorenzo BP, Garcia AR, Herranz UA, Perez-Valderrama B, Yglesias JM, **Bellmunt J**: Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results. ASCO Meeting Abstracts 2014; 32: e16088.
26. Rodriguez-Moreno JF, Esteban E, Leandro-García LJ, Castellano D, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, **Bellmunt J**, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Polo SH, García-Donas J, Rodriguez-Antona C: Retrospective study assessing the association of single nucleotide polymorphisms in VEGFR3 and on-target toxicity in patients with advanced renal-cell carcinoma (RCC) treated with sunitinib.Genitourinary Cancers Symposium 2014; 32: 537.
27. Maeso IG, Castellano D, Balea BC, Esteban E, Arnillas QP, Leon M, Munarriz J, Rubio G, Buron JDC, Sanchez JG, Martin A, Garcia-Bueno JM, Garcia AR, Perez-Valderrama B, Herranz UA, **Bellmunt J**: Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience.Genitourinary Cancer Symposium 2014; 32: 235.

28. Sonpavde G, **Bellmunt J**, Rosenberg JE, Bajorin D, Regazzi AM, Choueiri T, Qu A, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Wong YN, Sridhar S, Ko YJ, Milowsky M, Galsky M, Pond GR: Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.Genitourinary Cancer Symposium 2014; 32: 336.
29. Leow J, Chang S, Choueiri T, **Bellmunt J:** Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies.Genitourinary Cancer Symposium 2014; 32: 330.
30. Martinez A, Hernandez A, Arpi O,Menendez S, Iarchouk N, Gavilan E, Bellosillo B, Arumí M, Rojo F, Mullane S, Choueiri T, Rovira A, Albanell J, Brake R, **Bellmunt J**: Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials. ASCO Meeting Abstracts 2015; 33: e15520.
31. Zhou CW, Mullane S, Werner L, Taplin ME, Fay A, Choueiri T, Takeda D, Bowden M, **Bellmunt J**: Role of *miR-21*, *miR372*, and *E2F1* as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.ASCO Meeting Abstracts 2015; 33: 4530.
32. de Velasco G, Fay A, Culhane A, Hakimi A, Voss MH, Tannir N, Tamboli P, Appleman L, **Bellmunt J**, Rathmell K, Albiges L, Hsieh J, Heng D, Signoretti S, Choueiri T: Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.ASCO Meeting Abstracts 2015; 33: 4560.
33. Mullane S, Werner L, Zhou C, Taplin ME, Choueiri T, **Bellmunt J**, Bowden M: Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.ASCO Meeting Abstracts 2015; 33: e15518.
34. Plimack E, **Bellmunt J**, Gupta S, Berger R, Montgomery R, Heath K, Juco J, Emancipator K, Pathiraja K, Lunceford J, Perini R, O'Donnell P: Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.ASCO Meeting Abstracts 2015; 33: 4502.
35. **Bellmunt J**, Valderrama BP, Font A, Virizuela JA, Climent MA, Polo SH, Mellado B, Laínez N, del Alba A, Arranz JA, Guzman JCV, del Mar Llorente M, Castellano D, Gallardo E, del Muro X, Anido U, Domenech M, Puente J, Gracia J, García-Donas J: Maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC): Preliminary analysis of a randomized placebo controlled phase II trial (MAJA trial)—SOGUG 2011-02. ASCO Meeting Abstracts 2015; 33: 4529.
36. Bajorin D, Plimack E, Siefker-Radtke A, Choueiri T, De Wit R, Sonpavde G, Gipson A, Brown H, Mai Y, Pang L, Perini R, **Bellmunt J**: KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.ASCO Meeting Abstracts 2015; 33: TPS4572.
37. **Bellmunt J**, Sonpavde G, De Wit R, Choueiri T, Siefker-Radtke A, Plimack E, Lewis N, Brown H, Mai Y, Gause C, Kaufman D, Bajorin D: KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.ASCO Meeting Abstracts 2015; 33: TPS457.
38. **Bellmunt J**, Eigl B, Senkus-Konefka E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar S, Sternberg C, Retz M, Blumenstein B, Jacobs C, Stewart P, Petrylak D: First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.ASCO Meeting Abstracts 2015; 33: 4503.
39. Sonpavde G, Pond G, Rosenberg J, Bajorin D, Regazzi A, Mullane S, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Ko YJ, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Milowsky M, Choueiri T, **Bellmunt J**: Externally validated improved 5-factor prognostic

model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). ASCO Meeting Abstracts 2015; 33: 4527.

40. Cejas P, Mullane S, Van Allen E, Barletta J, Bowden M, Taplin ME, Pomerantz M, Choueiri T, Kwiatkowski D, Long H, **Bellmunt J:** Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).ASCO Meeting Abstracts 2015; 33: e15519.
41. Chen YW, Gelpi-Hammerschmidt F, Wu CP, **Bellmunt J**, Chang S: Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis.ASCO Meeting Abstracts 2015; 33: e15634.
42. Bambury R, Jordan E, Zabor E, Bouvier N, Al-Ahmadie H, Boyd M, Mullane S, Cha E, Ostrovnaya I, Hyman D, Bochner B, Arcila M, Solit D, Bajorin D, **Bellmunt J**, Berger M, Iyer G, Rosenberg J: Association of somatic mutations in DNA damage repair (DDR) genes with efficacy of platinum-based chemotherapy in advanced urothelial carcinoma.ASCO Meeting Abstracts 2015; 33: 4532.
43. Harshman L, Werner L, Wong YN, Yu E, Alva A, Crabb S, Powles T, Rosenberg J, Baniel J, Vaishampayan U, Berthold D, Ladoire S, Hussain S, Milowsky M, Agarwal N, Necchi A, Pal S, Recine F, **Bellmunt J**, Galsky M: Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC). ASCO Meeting Abstracts 2015; 33: 4524.
44. Fay A, Kwiatkowski D, Gray K, Thorner A, Rini B, Agarwal N, Ho T, Song J, Barrios P, Albiges L, Van Allen E, Krajewski K, Porta C, Pal S, **Bellmunt J**, McDermott D, Heng D, Signoretti S, Choueiri T: Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. ASCO Meeting Abstracts 2015; 33: 4519.
45. Petrylak D, Powles T, **Bellmunt J**, Braiteh F, Loriot Y, Zambrano C, Burris H, Kim J, Teng S, Bruey JM, Hegde P, Abidoye O, Vogelzang N: A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). ASCO Meeting Abstracts 2015; 33: 4501.
46. McKay R, Werner L, Harshman L, **Bellmunt J**, Sweeney C, Rosenberg J, Van Allen E, Walsh M, Vaishampayan U, McDermott D, Choueiri T: A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. ASCO Meeting Abstracts 2015; 33: 4559.
47. Hahn N, Picus J, Bambury R, Pal S, Hart L, Grivas P, Milowsky M, Alva A, Sonpavde G, Mortazavi A, **Bellmunt J**, Guancial E, Gupta S, Chao R, Collier M, Christensen J, Chen I, Rosenberg J: A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes. ASCO Meeting Abstracts 2015; 33: TPS4575.
48. Fay A, Van Allen E, Murray B, Albiges L, Signoretti S, Ho T, Hakimi A, Mickey S, Stanton M, **Bellmunt J,** McDermott D, Atkins M, Garraway L, Kwiatkowski D, Choueiri T: Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). Genitourinary Cancers Symposium 2015; 33: 422.
49. Martinez A, Hernandez A, Arpi O, Menendez S, Iarchouk N, Gavilan E, Bellosillo B, Arumí M, Rojo F, Mullane S, Choueiri T, Rovira A, Albanell J, Brake R, **Bellmunt J**: Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials. ASCO Meeting Abstracts 2015; 33: 369.
50. O'Donnell P, Plimack E, **Bellmunt J**, Berger R, Montgomery R, Heath K, Dolled-Filhart M, Pathiraja K, Gause C, Cheng J, Perini R, Gupta S: Pembrolizumab (Pembro; MK-3475) for

advanced urothelial cancer: Results of a phase IB study. Genitourinary Cancers Symposium 2015; 33: 296.

51. Mullane S, Zhou C, Martin-Doyle W, Loda M, Choueiri T, **Bellmunt J**, Bowden M: miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel. Genitourinary Cancers Symposium 2015; 33: 364,
52. Harshman L, Jacobus S, Mullane S, Feldman H, Hirsch M, Kantoff P, Choueiri T, **Bellmunt J**: Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).Genitourinary Cancers Symposium 2015; 33: 365.
53. Sonpavde G, Pond G, Rosenberg J, Bajorin D, Regazzi A, Choueiri T, Mullane S, Niegisch G, Albers P, Necchi A, di Lorenzo G, Fougeray R, Galsky M, Sridhar S, Ko YJ, Milowsky M, **Bellmunt J**: Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.Genitourinary Cancers Symposium 2015; 33: 311.
54. Ramos J, Casey M, Crabb S, Bamias A, Harshman L, Wong YN, **Bellmunt J**, De Giorgi U, Ladoire S, Powles T, Pal S, Niegisch G, Sternberg C, Alva A, Agarwal N, Necchi A, Vaishampayan U, Rosenberg J, Galsky M, Yu E: Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT). Genitourinary Cancers Symposium 2015; 33: 318.
55. **Bellmunt J**, Guo G, Mullane S, Orsola A, Werner L, Van Hummelen P, Thorner A, Loda M, Choueiri T,. Barletta J, Kwiatkowski D, Meyerson M, Van Allen E: Genomic landscape of high-grade T1 micropapillary bladder tumors. Genitourinary Cancers Symposium 2015; 33: 299.
56. Urun Y, Leow J, Fay A, Albiges L, Choueiri T, **Bellmunt J**: ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis. Genitourinary Cancers Symposium 2015; 33: 351.
57. Kim J, **Bellmunt J**, Powles T, Loriot Y, Vogelzang N, Zambrano C, Burris H, Teng S, Shen X, Bruey JM, Boyd Z, Hegde P, Petrylak D: Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. Genitourinary Cancers Symposium 2015; 33: 297.
58. Carles J, Diaz E, Domenech M, Font A, **Bellmunt J,** Mellado B, Suárez C, Bonfill T, Saez M, Guix M, Mendez M, Maroto P, de Portugal T, Figols M, Luque R, Aldabo R, Morales R, Bonet M, Maldonado X, Foro P: A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity. Genitourinary Cancers Symposium 2015; 33: 15.

Narrative Report

My contributions as a clinician, researcher, and teacher have been well balanced.

I served as Section Chief, Solid Tumor Oncology (GU/GI) at Hospital del Mar in Barcelona for 7 years. Many patients with GU cancer—especially bladder carcinoma—were referred to me for consultation. I saw patients over 2 clinic days per week. The clinical practice included 7 full-time GU/GI oncologists, 1 laboratory-based GU oncologist, 1 dedicated GU research nurse, and 1 dedicated study coordinator.

In my research, I have focused on the development of new systemic treatments for cancers--in particular, bladder cancer—and the search for prognostic factors and potential therapeutic targets. I developed the MCAVI (methotrexate, carboplatin and vinblastine) schedule for unfit patients (*Cancer* 1992) as the control arm for the EORTC 30986 study vs. g GemCarbo (gemcitabine carboplatin) (*JCO* 2010). I

reported the superiority of cisplatin vs. carboplatin in the randomized trial of MVAC (methotrexate, vinblastine, adriamycin and cisplatinum) vs. MCAVI (*Cancer* 1997). To improve the combination of CG (Cisplatin/Gemcitabine), we conducted an investigational phase I / II study with the 3-drug regimen of PCG (paclitaxel, cisplatin and gemcitabine) *(JCO* 2000). In 2001, we reported the feasibility study of the combination of GemCarbo (*EurJCancer*), which was used as the experimental arm of the EORTC 30986 study for a randomized trial of patients unfit for platinum (*JCO* 2012).

We confirmed the value of the MSKCC prognostic factors in the first-line treatment with chemotherapy in bladder cancer (TCG [paclitaxel, cisplatin, and gemcitabine] study, *Cancer* 2002). We also described, in the same group of patients, the role of ERCC1 expression as a predictor of CDDP (cisplatin) response in bladder cancer (*Ann Oncol* 2007).

Within the EORTC, I was the chairman of the Advanced Bladder Cancer Committee, and study Chair and co-chair for the 30987 and 30986 studies. To confirm the results of triple therapy with TCG, we designed the 30987 study, the largest study conducted in advanced bladder cancer comparing CG versus TCG (*JCO* 2012).

Looking for second-line options in patients failing platinum, we reported the phase III study of vinflunine versus placebo, which led to the approval of vinflunine in the European Union (*JCO* 2009). Based on this study, the role of prognostic factors in second-line treatment was described (*JCO* 2010).

In the area of new therapeutic targets, we reported the study of sunitinib in front-line therapy. In collaboration with Jonathan Rosenberg (DFCI), we analyzed the molecular profile of the Spanish bladder cancer patient series (ASCO 2011). Based on findings of PI3K mutations, we are studying in preclinical models the efficacy of PI3K and TOR1-2 inhibitor drugs in bladder cancer cell lines.

Since last 2014, the increased interest of Immunotherapy in bladder cancer (Nature 2014) has lead to the development of a translational/clinical program in collaboration with Sabina Signoretti, David Kwiatkowsky and Eli Van Allen, in order to discover predictors of response/resistance. In the clinical area, three Immunotherapy trials have been implemented in urothelial tumors. I have been assigned to the role of Global PI of the phase III Pembrolizumab in second line bladder cancer.

In RCC, the innovative contribution has been the clinical study exploring the role of the chemotherapy switch benefit described in the preclinical models by Dr. Douglass Hanahan.

My teaching duties have ranged from preceptor to UPF (Pompeu Fabra University) medical students, mentor to medical oncology residents and junior staff (Hospital del Mar), and presenter of national and international talks. Currently at DFCI I have the chance to teach and mentor several of our residents and oncology fellows in the clinical and translational field of urothelial cancer. This gives a great personal and professional satisfaction as well as providing me with some very gratifying feedback. My passion for teaching is also fulfilled by the mentoring of two outstanding recently licensed doctors on their way to Urology and Oncology Residency; Dr. Jeffrey Leow and Dr.William Martin-Doyle. Both of them have finished a Masters in the School of Public Health at Harvard and have worked closely with me to use state of the art and modern meta-analysis tools to pool together all the information on urothelial bladder and upper urinary tract tumors.

Since taking on my new DFCI role in March 2013, I have assumed the duties of Director of the Bladder Cancer Center and contributed to GU patient care, primarily bladder cancer patients. In addition to my clinical contributions, I assisted in the preliminary preparation of an application, with a letter of interest,

for a grant in the area RFA-CA-12-018 (PQB3): Research Answeres to NCI's Provocative Questions-Group B (R21): "Evaluating the functional consequences-recurrence and progression-of epigenetic mutations derived from pT1G3 bladder tumor sequencing." I was also involved in the submission of a proposal involving PROFILE, and using the OncoMap system and other clinical/research data for analysis in non-prostate GU tumors (urothelial transitional/non-transitonal, penile, adrenal, and kidney), in collaboration with Dr. Toni Choueiri. I was involved in the innovative design of the new DFCI Bladder CRIS project and participated in the roll-out process for the four core GMAPs (GU-Management & Assessment Pathways), which include Prostate, Bladder, Renal and Testicular cancer, with dedicated involvement in bladder cancer pathways.

While at DFCI, I have continued to pursue my interest in mentoring and teaching by advising a group of Harvard students on the project "Adjuvant Chemotherapy in Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-analysis of Randomized Trials" (Eur Urol, epub Aug. 28) as well as lecturing on bladder cancer for the Medical Oncology recertification exam. I serve on the GU oncology tumor at BWH on a monthly basis and have served as the director of the GU seminars since September, 2014.

Aside from my role as the Director of the Bladder Cancer Center, I also currently serve as the Chairman of the CRIS/Gelb Center at DFCI since November 2015. The main clinical achievement has been to be the Global PI of the phase III Pembrolizumab in second line urothelial cancer. This trial just showed positive overall survival results and we expect this results to be practice changing (analysis ongoing).

In addition, 22 Research Investigations and 18 Other Peer Reviewed Publications, several of them first- or senior-author contributions, have been published since then. Three new Clinical Guidelines are also in print.

I look forward to making future contributions to the Harvard community in terms of clinical expertise and innovation, research, administrative service, mentoring and teaching.